Press Releases
 |
|
| Date | Title | | | January 28, 2010 | Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due
2011 and Its 3½% Convertible Subordinated Notes Due 2011| WILMINGTON, Del., Jan 28, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) today announced that it will redeem
all of its outstanding 3½% Convertible Senior Notes due 2011 and all of
its outstanding 3½% Convertible Subordinated Notes due 2011 on February
22, 2010, at a price equal to 100.5% of the principal amount of the
notes plus accrued and unpaid interest to the redemption date. The
notice of redemption was sent to the holders of the outstandi... |
|  | | January 05, 2010 | Incyte to Present at the 28th Annual
JPMorgan Healthcare Conference| WILMINGTON, Del., Jan 05, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the
28th Annual JPMorgan Healthcare Conference on Tuesday,
January 12, 2010 at 9:30 a.m. PT / 12:30 p.m. ET. Presenting for Incyte
Corporation will be Paul Friedman, M.D., president and chief executive
officer.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A repla... |
| | | December 21, 2009 | Incyte to Host Conference Call to Discuss Its Collaboration with Lilly for the Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies| Conference Call Scheduled Today at 8:30 a.m. ETWILMINGTON, Del., Dec 21, 2009 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a conference call for 8:30 a.m. ET on Monday, December 21, 2009.
Conference Call: December 21, 2009 at 8:30 a.m. ET
Domestic Dial In Number: 877-407-8037
International Dial In Number: 201-689-8037
Conference ID # 340419
If you are unable to participate, a replay of the conference call will be available for thirty d... |
| | | December 21, 2009 | Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies| Lilly Gains Worldwide Rights for Incyte's Novel JAK1/JAK2 Inhibitor, INCB28050, for Inflammatory and Autoimmune DiseasesIncyte to Receive $90 Million Upfront Payment and up to $665 Million in Potential Milestones, Plus Royalties on Future Sales; Incyte Retains Co-Development & Co-Promotion OptionsINDIANAPOLIS and WILMINGTON, Del., Dec 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced today that they have entered in... |
| | | December 12, 2009 | Data from a Phase I/II Study Presented at the 32nd
San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination
with Trastuzumab May Improve Clinical Response Rates in HER2 Positive
Patients with Advanced Metastatic Disease| WILMINGTON, Del., Dec 12, 2009 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today positive results from
an ongoing Phase I/II clinical trial for its selective oral sheddase
inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic
breast cancer. The results suggest that, when compared to a historical
control study of trastuzumab as monotherapy, INCB7839 in combination
with trastuzumab provided improvements in time to progres... |
| | | December 07, 2009 | Data from Three Phase II Trials to be Presented at the 51st American Society of Hematology Annual Meeting Demonstrate that INCB18424, a Selective JAK1/JAK2 Inhibitor, Has Potential in Multiple Hematology Conditions|
Continues to Demonstrate Rapid and Durable Clinical Benefits in Myelofibrosis Patients
Provides Clinically Meaningful Improvements in Patients with Advanced Polycythemia Vera and Essential Thrombocythemia
Demonstrates Clinical Benefit in Patients with Secondary Acute Myeloid Leukemia
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 7, 2009-- Incyte Corporation (NASDAQ: INCY) announced this morning that INCB18424 (also referred to as INCB018424), its selective, orally available janus kinase ... |
| | | December 02, 2009 | Incyte to Host Webcast at 51st American Hematology Annual Meeting| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 2, 2009--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
a webcast for 8:30 p.m. CT / 9:30 p.m. ET on Monday, December 7, 2009 to
discuss clinical results for its lead JAK 1/JAK 2 inhibitor, INCB18424,
which will be the subject of three oral presentations at the 51st
American Hematology Annual Meeting in New Orleans.
A Phase II Study of INCB018424, An Oral, Selective... |
| | | November 25, 2009 | Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs|
Novartis to Develop and Commercialize Incyte’s Lead JAK1/JAK2
Inhibitor, INCB18424, for Territories Outside the US and Incyte’s cMET
Inhibitor, INCB28060, Worldwide
Incyte May Receive Over $1 Billion in Payments, Including $150
Million Upfront Plus an Immediate $60 Million Development
Milestone in Addition to Future Potential Milestones and Royalties
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 25, 2009--
Incyte Corp... |
| | | November 05, 2009 | Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs|
Conference Call Scheduled Today at 8:30 a.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 5, 2009--
Incyte Corporation (Nasdaq:INCY) today reported third quarter 2009
financial results and provided an update on its lead programs.
Paul A. Friedman, M.D., Incyte's President and Chief Executive Officer,
stated, "We recently raised over $500 million in our common stock and
senior convertible notes offerings, which we intend to use to comple... |
| | | October 20, 2009 | Incyte to Report Third Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on November 5| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 20, 2009--
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled
its third quarter 2009 financial results conference call for 8:30 a.m.
ET on Thursday, November 5, 2009. The schedules for the press release
and conference call are as follows:
Q3 2009 Press Release:
... |
| | | September 30, 2009 | Incyte to Present at the Fourth Annual JMP Securities Healthcare Focus Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 30, 2009--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Fourth Annual JMP Securities Healthcare Focus Conference on Monday,
October 5, 2009 at 10:30 a.m. ET. Presenting for Incyte Corporation will
be Paul Friedman, M.D., president and chief executive officer.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcas... |
| | | September 30, 2009 | Incyte Announces Closing of Public Offering of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 30, 2009--
Incyte Corporation (Nasdaq:INCY) today announced the closing of its
public offering of 20,700,000 shares of its common stock at a price to
the public of $6.75 per share, which includes 2,700,000 shares sold upon
exercise by the underwriters of their option to purchase additional
shares. The net proceeds to Incyte from the offering are approximately
$132.0 million, after deducting the underwriting dis... |
| | | September 30, 2009 | Incyte Completes Offering of Convertible Senior Notes| WILMINGTON, Del., Sep 30, 2009 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) today announced that it has completed
its previously announced private placement of $400.0 million aggregate
principal amount of 4.75% Convertible Senior Notes due 2015, including
notes issued upon the exercise in full of the initial purchasers' option
to purchase additional notes. Incyte estimates that the net proceeds
from this offering will be approximately $387.3 million... |
| | | September 24, 2009 | Incyte Prices $350 Million Convertible Senior Notes Offering| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 24, 2009--
Incyte Corporation (Nasdaq: INCY) today announced the pricing of its
offering of $350 million aggregate principal amount of 4.75% Convertible
Senior Notes due 2015 in a private placement to qualified institutional
buyers pursuant to exemptions from the registration requirements of the
Securities Act of 1933. The size of the offering was increased from the
originally announced $250 million aggregate p... |
| | | September 24, 2009 | Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 24, 2009--
Incyte Corporation (Nasdaq:INCY) today announced the pricing of its
underwritten public offering of 18,000,000 shares of its common stock at
a price to the public of $6.75 per share. The offering is expected to
close on September 30, 2009, subject to customary closing conditions.
Incyte also granted the underwriters a 30-day option to purchase an
additional 2,700,000 shares of common stock. All of th... |
| | | September 22, 2009 | Incyte Announces Proposed Public Offering of 18,000,000 Shares of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 22, 2009--
Incyte Corporation (Nasdaq:INCY) today announced that it intends to
offer to sell, subject to market and other conditions, 18,000,000 shares
of its common stock in an underwritten public offering. In connection
with the offering, the Company expects to grant the underwriters a
30-day option to purchase an additional 2,700,000 shares of common
stock. All of the shares will be offered by the Company.
... |
| | | September 22, 2009 | Incyte Announces Proposed Offering of $250 Million Convertible Senior Notes| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 22, 2009--
Incyte Corporation (Nasdaq:INCY) today announced that it intends to
offer, subject to market and other conditions, up to $250 million
aggregate principal amount of Convertible Senior Notes due 2015 in a
private placement to qualified institutional buyers pursuant to
exemptions from the registration requirements of the Securities Act of
1933. The notes will bear interest, and will be convertible, in c... |
| | | September 21, 2009 | Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 21, 2009--
Incyte Corporation (Nasdaq:INCY) announced positive clinical trial
results for a topical formulation of its lead janus kinase (JAK)
inhibitor, INCB18424, in psoriasis. These results were obtained from a
multi-center three-month Phase IIb trial comparing three once-daily
doses of topical INCB18424 to vehicle in 200 patients with
mild-to-moderate psoriasis. In the trial patients treated with INCB18424
... |
| | | September 03, 2009 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del., Sep 03, 2009 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences:
Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at
10:00 a.m. (ET) in New York City;
2009 Morgan Stanley Global Healthcare Unplugged Conference on Tuesday,
September 15, 2009 at 11:30 a.m. (ET) in New York City; and
UBS 2009 Global Life Sciences Confer... |
| | | July 30, 2009 | Incyte Reports Second Quarter 2009 Financial Results and Provides Update on Drug Development Programs| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 30, 2009--
Incyte Corporation (Nasdaq:INCY) today reported second quarter 2009
financial results and provided an update on its highest priority
clinical programs.
"With the Phase III registration trials for our lead JAK1/JAK2
inhibitor, INCB18424, now underway in both the U.S. and Europe; the
launch of a six-month Phase II trial for our second JAK1/JAK2 inhibitor,
INCB28050, in rheumatoid arthr... |
| | | July 21, 2009 | Incyte Reaches Agreement with FDA on a Special Protocol Assessment for INCB18424 in Myelofibrosis| COMFORT- I, a Pivotal Phase III Clinical Trial, to Begin in the United States, Canada and Australia
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 21, 2009--
Incyte Corporation (Nasdaq:INCY) announced today that it has reached
agreement with the U.S. Food and Drug Administration (FDA) regarding a
Special Protocol Assessment (SPA) on the design of a pivotal Phase III
trial for its lead JAK1/JAK2 Inhibitor, INCB18424, in patients with
primary myelofibrosis (PMF), p... |
| | | July 15, 2009 | Incyte to Report Second Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on July 30| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 15, 2009--
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled
its second quarter 2009 financial results conference call for 8:30 a.m.
ET on Thursday, July 30, 2009. The schedules for the press release and
conference call are as follows:
Q2 20... |
| | | June 06, 2009 | Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte's Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Cholesterol in Patients with Type 2 Diabetes| A Live Webcast & Conference Call to Discuss These Results Are Scheduled for Sunday, June 7, 2009, 5:00 p.m. ET / 4:00 p.m. CT
NEW ORLEANS & WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 6, 2009--
Incyte Corporation (Nasdaq:INCY) announced today clinical results of its
Phase IIb trial of INCB13739, an orally bioavailable inhibitor of the
enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), at the
American Diabetes Association (ADA) 69th Scientific Sessions b... |
| | | May 28, 2009 | Incyte Provides Update on Special Protocol Assessment for INCB18424 as a New Treatment for Myelofibrosis| Announces Plan to Initiate a Phase III Registration Trial in Europe in June
WILMINGTON, Del.--(BUSINESS WIRE)--May. 28, 2009--
Incyte Corporation (Nasdaq:INCY) announced today that based on recent
input from the U.S. Food and Drug Administration (FDA) regarding
Incyte’s request for a Special Protocol Assessment (SPA) for INCB18424
for patients with primary myelofibrosis (PMF), post-polycythemia vera
myelofibrosis (PPV-MF) and post-essential thrombocythemia... |
| | | May 26, 2009 | Incyte to Present at Goldman Sachs 30th Annual Global Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--May. 26, 2009--
Incyte Corporation (Nasdaq:INCY) announced today it will participate in
the Goldman Sachs 30th Annual Global Healthcare Conference on
Tuesday, June 9, 2009 at 10:45 a.m. (Eastern Time). Presenting for
Incyte Corporation will be Paul Friedman, M.D., president and chief
executive officer.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations... |
| | | May 07, 2009 | Incyte Reports First Quarter 2009 Financial Results and Provides Update on Drug Development Programs| WILMINGTON, Del.--(BUSINESS WIRE)--May. 7, 2009--
Incyte Corporation (Nasdaq:INCY) today reported first quarter 2009
financial results and provided an update on its highest priority
clinical programs.
“We continued to make good progress in our lead clinical programs during
the first quarter. Thus, over the next few months we expect a number of
key events, including the initiation of Phase III trials for INCB18424
in patients wi... |
| | | April 21, 2009 | Incyte to Report First Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on May 7| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 21, 2009--
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled
its first quarter 2009 financial results conference call for 8:30 a.m.
ET on Thursday, May 7, 2009. The schedules for the press release and
conference call are as follows:
... |
| | | March 24, 2009 | Incyte to Present at Citi's 4th Annual Biotech Day Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 24, 2009--
Incyte Corporation (Nasdaq:INCY) announced today it will present at
Citi's 4th Annual Biotech Day Conference on Wednesday, April
1, 2009 at 11:20 a.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of Incyte,
will provide an overview of the company and discuss its most advanced
drug discovery and development programs.
The presentation will be web... |
| | | March 09, 2009 | Incyte to Present at Cowen and Company 29th Annual Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 9, 2009--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Cowen and Company 29th Annual Health Care Conference on
Monday, March 16, 2009 at 3:10 p.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of Incyte,
will provide an overview of the company and discuss its most advanced
drug discovery and development programs.
The presentation... |
| | | February 18, 2009 | Incyte Reports Fourth Quarter and Year-End 2008 Financial Results; Announces 2009 Financial Guidance| Conference Call Scheduled for Wednesday, February 18, 2009 at 8:30 a.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 18, 2009--
Incyte Corporation (Nasdaq:INCY) today reported fourth quarter and
year-end 2008 financial results and described its product development
priorities and financial guidance for 2009.
Paul A. Friedman, M.D., Incyte’s President and Chief Executive Officer,
stated: “We made significant clinical progress in 2008 including the
... |
| | | February 04, 2009 | Incyte to Report 2008 Financial Results and 2009 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18| WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter and year-end 2008 financial results conference call
for 8:30 a.m. ET on Wednesday, February 18, 2009. The schedules for the
press release and conference call are as follows:
... |
| | | January 13, 2009 | Incyte to Announce 2009 Objectives at JPMorgan Healthcare Conference; JAK Inhibitor Program Highest Priority| A Live and Archived Copy of the Presentation Will Be Available on Incyte's Website on January 13, 2009, Beginning at 3:30 pm PT/6:30 pm ET
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 13, 2009--Incyte Corporation (Nasdaq:INCY) will announce today at the 27th Annual
JPMorgan Healthcare Conference its 2009 corporate objectives, including
its decision to focus on clinical programs with the greatest near-term
value.
These programs include:
Janus kin... |
| | | January 05, 2009 | Incyte to Present at the 27th Annual JPMorgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 5, 2009--Incyte Corporation (Nasdaq:INCY) announced today it will present at the
27th Annual JPMorgan Healthcare Conference on Tuesday,
January 13, 2009 at 3:30 p.m. (Pacific Time) / 6:30 p.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of Incyte,
will provide an overview of the company and discuss its most advanced
drug discovery and development programs.
The pres... |
| | | December 06, 2008 | Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients| Incyte to Present Additional Data at 50th American Society of Hematology Annual Meeting in San Francisco
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 6, 2008--Incyte Corporation (Nasdaq: INCY) will present updated results from an
ongoing Phase II trial of INCB18424, its selective, orally available
Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the
50th American Society of Hematology (ASH) Annual Meeting.
MF is a serious neoplastic conditi... |
| | | November 20, 2008 | Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference| WILMINGTON, Del., Nov 20, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the
20th Annual Piper Jaffray Health Care Conference on
Wednesday, December 3, 2008 at 11:00 a.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of Incyte,
will provide an overview of the company and discuss its most advanced
drug discovery and development programs.
The presentation will be webcast live and can be ac... |
| | | November 06, 2008 | Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results| Conference Call Scheduled for Thursday, November 6, at 8:30 a.m.
ET
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 6, 2008--Incyte
Corporation (Nasdaq:INCY) today announced its third quarter 2008
financial results and reported continued progress in multiple clinical
programs.
Paul Friedman, M.D., President and CEO of Incyte, stated,
"Recently presented clinical data for our lead JAK inhibitor,
INCB18424, continue to support its broad therapeutic potent... |
| | | October 30, 2008 | Incyte to Present at 2008 DB-Biotech Boston Confab| WILMINGTON, Del., Oct 30, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the
2008 Deutsche Bank Biotech Boston Confab on Tuesday, November 11, 2008
at 11:25 a.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of Incyte,
will provide an overview of the company and discuss its most advanced
drug discovery and development programs.
The presentation will be webcast live and can be accessed at... |
| | | October 26, 2008 | Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients| Complete Results from 28-day Phase IIa Clinical Trial Presented at
the 2008 American College of Rheumatology Annual Scientific Meeting
A Webcast and Conference Call to Discuss These Results Are
Scheduled for Tonight at 10:30 P.M. Eastern Time / 7:30 P.M. Pacific
Time
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 26, 2008--Incyte
Corporation (Nasdaq:INCY) announced today the presentation of clinical
results from a 28-day Phase IIa trial of INCB1842... |
| | | October 23, 2008 | Incyte to Report Third Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on November 6| WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte Corporation (Nasdaq:INCY) announced today that it has
scheduled its third quarter 2008 financial results conference call for
8:30 a.m. ET on Thursday, November 6, 2008. The schedules for the
press release and conference call are as follows:
Q3 2008 Press Release: November 6, 2008 at 7:00 a.m. ET
Q3 2008 Conference Call: November 6, 2008 at 8:30 a.m. ET
Domestic Dial In Number: 877-407-8037
International Dial In Number: 20... |
| | | October 23, 2008 | Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time| WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte Corporation (Nasdaq:INCY) announced today that it has
scheduled a webcast and conference call for 10:30 p.m. Eastern Time /
7:30 p.m. Pacific Time on Sunday, October 26, 2008 to discuss clinical
results from a Phase IIa trial of INCB18424, its oral JAK 1&2
inhibitor, in patients with rheumatoid arthritis. Results from the
Phase IIa trial will be presented at the 2008 American College of
Rheumatology (ACR) Annual Scientific Meeting that is bei... |
| | | September 30, 2008 | Incyte to Present at JMP Securities Third Annual Healthcare Focus Conference| WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte Corporation (Nasdaq:INCY) announced today it will present
at the JMP Securities Third Annual Healthcare Focus Conference on
Monday, October 6, 2008 at 11:00 a.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com un... |
| | | September 18, 2008 | Incyte Appoints Chief Commercial Officer| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 18, 2008--Incyte
Corporation (Nasdaq:INCY) announced today the appointment of Patricia
S. Andrews as executive vice president and chief commercial officer, a
new position reporting to Paul Friedman, M.D., Incyte's president and
chief executive officer. Ms. Andrews will join Incyte on October 20,
2008.
Ms. Andrews has held a broad range of strategic planning and
commercial positions at Pfizer since 1991. She was most recently vice
president... |
| | | September 18, 2008 | Incyte's Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients with Mild to Moderate Psoriasis| Results Presented Today at the 17th Congress of European Academy
\ of Dermatology and Venereology
WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 18, 2008--Incyte
Corporation (Nasdaq:INCY) reported positive results from two 28-day
Phase IIa clinical trials of topical INCB18424, a selective
janus-associated kinase (JAK) inhibitor, in patients with mild to
moderate psoriasis. Results from the first study (Study 201), a Phase
IIa dose-escalation trial involving 28 patients, demon... |
| | | September 16, 2008 | Incyte to Present at the UBS Global Life Sciences Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 16, 2008--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the 2008
UBS Global Life Sciences Conference on Tuesday, September 23, 2008 at
8:00 a.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com... |
| | | August 27, 2008 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del., Aug 27, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences:
--
3rd Annual Citi Biotech Day on Monday,
September 8, 2008 at 3:45 p.m. (ET) in New York City;
--
Morgan Stanley Global Healthcare Unplugged Conference on Tuesday,
September 9, 2008 at 9:10 a.m. (ET) in New York City; and
--
Baird 2008 Small Cap Healthcare Conference on Wednesday, S... |
| | | August 06, 2008 | Incyte Announces Closing of Public Offering of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 6, 2008--Incyte
Corporation (Nasdaq:INCY) today announced the closing of its public
offering of 12,075,000 shares of its common stock at a price to the
public of $9.00 per share, which includes 1,575,000 shares sold upon
exercise by the underwriters of their option to purchase additional
shares. The net proceeds to Incyte from the offering are approximately
$101.8 million, after deducting the underwriting discount and
estimated offering expenses... |
| | | July 31, 2008 | Incyte Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--July 31, 2008--Incyte
Corporation (Nasdaq:INCY) today announced the pricing of its
underwritten public offering of 10,500,000 shares of its common stock
at a price to the public of $9.00 per share. The size of the offering
was increased from the originally announced 9,000,000 shares. Incyte
also granted the underwriters a 30-day option to purchase an
additional 1,575,000 shares of common stock. All of the shares are
being offered by Incyte.
The ... |
| | | July 29, 2008 | Incyte Announces Proposed Public Offering of 9,000,000 Shares of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--July 29, 2008--Incyte
Corporation (Nasdaq:INCY) today announced that it intends to offer to
sell, subject to market and other conditions, 9,000,000 shares of its
common stock in an underwritten public offering. In connection with
the offering, the Company expects to grant the underwriters a 30-day
option to purchase an additional 1,350,000 shares of common stock from
the Company to cover any over-allotments. All of the shares will be
offered by the C... |
| | | July 29, 2008 | Incyte Reports Progress in Multiple Clinical Programs; Announces Second Quarter Financial Results| NOTE: Conference Call Now Scheduled for Tomorrow Morning,
Wednesday, July 30 at 8:00 a.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)--July 29, 2008--Incyte
Corporation (Nasdaq:INCY) today announced its second quarter 2008
financial results and reported continued progress in several lead
clinical programs.
Paul Friedman, M.D., President and CEO of Incyte, stated, "During
the second quarter, we presented clinical findings at several
scientific conferences from our ong... |
| | | July 22, 2008 | Incyte to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on July 31| WILMINGTON, Del.--(BUSINESS WIRE)--July 22, 2008--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
second quarter 2008 financial results conference call for 8:30 a.m. ET
on Thursday, July 31, 2008. The schedules for the press release and
conference call are as follows:
Q2 2008 Press Release: July 31, 2008 at 7:00 a.m. ET
Q2 2008 Conference Call: July 31, 2008 at 8:30 a.m. ET
Domestic Dial In Number: 877-407-8037
Internati... |
| | | June 12, 2008 | Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study| Results Presented Today at the EULAR 2008 Congress in ParisWILMINGTON, Del., Jun 12, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today the presentation
of clinical results from a 28-day Phase IIa trial of INCB18424, its
orally available janus-associated kinase (JAK) inhibitor, in patients
with rheumatoid arthritis (RA). Results from the first of four
treatment groups, involving 12 treated and 4 placebo patients,
demonstrated that the 15 mg twice-daily dose of INCB1842... |
| | | June 11, 2008 | Incyte to Host EULAR Webcast and Conference Call on June 12| WILMINGTON, Del.--(BUSINESS WIRE)--June 11, 2008--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled a
webcast and conference call for 8:30 a.m. ET on Thursday, June 12,
2008 to discuss clinical results from a Phase IIa trial of INCB18424
in patients with rheumatoid arthritis that will be presented at the
European League Against Rheumatism Congress 2008 currently being held
in Paris.
The schedules for the press release, webcast and conference call
are as follo... |
| | | June 09, 2008 | Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics| Results Presented at the American Diabetes Association 68th
Scientific Sessions
WILMINGTON, Del.--(BUSINESS WIRE)--June 9, 2008--Incyte
Corporation (Nasdaq:INCY) announced clinical results presented today
at the American Diabetes Association 68th Scientific Sessions of its
Phase IIa trial of INCB13739, an orally bioavailable inhibitor of the
11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme. These
results showed that 28 days of treatment wit... |
| | | June 03, 2008 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--June 3, 2008--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences:
Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
on Tuesday, June 10, 2008 at 9:15 a.m. (PT) / 12:15 p.m. (ET)
in Dana Point, California; and
Jefferies 2nd Annual Healthcare Conference on Wednesday, June
25, 2008 at 12:30 p.m. (ET) in New York.
The presentations will be webcast ... |
| | | June 02, 2008 | Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study| Results Presented Today at the 2008 American Society of Clinical
Oncology Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--June 2, 2008--Incyte
Corporation (Nasdaq: INCY) announced today the presentation of
clinical results from a Phase I/II study of INCB18424, its orally
available janus-associated kinase (JAK) inhibitor, in patients with
myelofibrosis. Myelofibrosis (MF) is a serious neoplastic condition
characterized by varying degrees of bone marrow failu... |
| | | April 30, 2008 | Incyte Reports First Quarter Financial Results and Positive Clinical Progress in Multiple Programs| Conference Call and Webcast Scheduled for 8:30 a.m. ET Today
WILMINGTON, Del.--(BUSINESS WIRE)--April 30, 2008--Incyte
Corporation (Nasdaq:INCY) today reported first quarter 2008 financial
results and reviewed recent clinical accomplishments in multiple
programs.
Paul Friedman, M.D., Incyte's President and CEO stated, "Our lead
JAK inhibitor compound, INCB18424, which has already generated
impressive proof-of-concept clinical results in myelofibrosis,
rheumatoid arthritis and... |
| | | April 17, 2008 | Incyte to Report First Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on April 30| WILMINGTON, Del.--(BUSINESS WIRE)--April 17, 2008--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
first quarter 2008 financial results conference call for 8:30 a.m. ET
on Wednesday, April 30, 2008. The schedules for the press release and
conference call are as follows:
Q1 2008 Press Release: April 30, 2008 at 7:00 a.m. ET
cQ1 2008 Conference Call: April 30, 2008 at 8:30 a.m. ET
Domestic Dial In Number: 877-407-8037
Intern... |
| | | April 17, 2008 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--April 17, 2008--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences:
Morgan Stanley Global Healthcare Unplugged Conference on
Thursday, May 1, 2008 at 10:40 a.m. (ET) in Key Biscayne,
Florida;
Banc of America 2008 Healthcare Conference on Wednesday, May
14, 2008 at 2:40 p.m. (PT) / 5:40 p.m. (ET) in Las Vegas; and
JMP Securities Seventh Annual Research Conference... |
| | | March 17, 2008 | Incyte to Provide Update on Clinical Programs at Cowen Health Care Conference| A live and archived copy of the presentation will be available on Incyte's website on March 17, 2008, at 3:15 pm ETWILMINGTON, Del., Mar 17, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) will announce today at the Cowen
and Company 28th Annual Health Care Conference results from its
initial meeting with the U.S. Food & Drug Administration (FDA)
regarding the development of its lead JAK inhibitor, INCB18424, for
myelofibrosis.
Paul Friedman, M.D., Incyte's President and CEO, state... |
| | | March 11, 2008 | Incyte to Present at the Cowen and Company 28th Annual Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--March 11, 2008--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the Cowen
and Company 28th Annual Health Care Conference on Monday, March 17,
2008 at 3:15 p.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.inc... |
| | | February 14, 2008 | Incyte Reports Progress in Multiple Clinical Programs; Expands JAK Inhibitor Program; Announces 2007 Financial Results and Provides 2008 Financial Guidance| Conference Call and Webcast Scheduled for 8:30 a.m. ET Today WILMINGTON, Del., Feb 14, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) today reported full year and
fourth quarter 2007 financial results, and announced its 2008
financial guidance and key objectives and plans for its rapidly
expanding clinical pipeline.
Paul A. Friedman, M.D., President and CEO of Incyte, stated, "Over
the past year, we've worked intensively to advance a number of our
internally-discovered compou... |
| | | February 05, 2008 | Incyte to Report 2007 Financial Results and 2008 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 14| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 5, 2008--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
fourth quarter and year-end 2007 financial results conference call for
8:30 a.m. ET on Thursday, February 14, 2008. The schedules for the
press release and conference call are as follows:
-- Q4 & YE 2007 Press Release: February 14, 2008 at 7:00 a.m. ET
-- Q4 & YE 2007 Conference Call: February 14, 2008 at 8:30 a.m. ET
-- Domestic Dial In Num... |
| | | January 08, 2008 | Incyte to Report Positive Clinical Results from JAK Inhibitor and 11beta-HSD1 Inhibitor Programs and Introduce New Metabolic Program at JPMorgan Healthcare Conference| A Live and Archived Copy of the Presentation Will Be Available on
Incyte's Website on January 8, 2008, Beginning at 9:30 am PT/12:30 pm
ET
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 8, 2008--Incyte
Corporation (Nasdaq:INCY) will announce today at the 26th Annual
JPMorgan Healthcare Conference further positive clinical
proof-of-concept results for several of its wholly-owned, internally
developed programs, including its JAK inhibitor for rheumatoid
... |
| | | January 02, 2008 | Incyte to Present at the 26th Annual JPMorgan Healthcare Conference| WILMINGTON, Del., Jan 02, 2008 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present
at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January
8, 2008 at 9:30 a.m. (Pacific Time) / 12:30 p.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
... |
| | | December 21, 2007 | Incyte Announces $8.5 million Gain from Sale of Investment| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 21, 2007--Incyte
Corporation today announced the receipt of approximately $8.5 million
as a result of the sale of Velocity11, a privately-held life sciences
technology company in which Incyte held an ownership position. Incyte
may receive additional consideration of approximately $900,000 after a
one year escrow period. As a result of the sale, Incyte will record a
gain of approximately $8.5 million in the fourth quarter of 2007.
Incyte Corp... |
| | | December 16, 2007 | Data Presented at the 30th San Antonio Breast Cancer Symposium Supports Further Development of INCB7839 as a New Oral Treatment for Breast Cancer| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 16, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that three scientific
posters have been presented at the 30th San Antonio Breast Cancer
Symposium describing the potential benefits of its selective sheddase
inhibitor, INCB7839, in the treatment of metastatic breast cancer.
INCB7839 is a novel, orally available ADAM metalloprotease
inhibitor that is designed to block activation of the epidermal growth
factor (EGFR) pathways. Curre... |
| | | December 10, 2007 | Data Presented At The American Society Of Hematology 49th Meeting Demonstrate That Incyte's Novel JAK Inhibitor, INCB18424, Provides Rapid and Profound Clinical Benefits in Myelofibrosis Patients| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 10, 2007--Incyte
(Nasdaq:INCY) announced today the presentation of interim Phase I/II
results of INCB18424, its orally available janus-associated kinase
(JAK) inhibitor in patients with myelofibrosis (MF). MF is a serious
neoplastic condition with a survival rate of 3 to 7 years that is
characterized by varying degrees of bone marrow failure,
life-threatening splenic enlargement, and marked constitutional
symptoms, resulting in a significant los... |
| | | December 05, 2007 | Incyte To Webcast A Discussion Of Its JAK Inhibitor, INCB18424, During The American Society Of Hematology 49th Annual Meeting| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 5, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that it will host a meeting
to discuss clinical data on INCB18424, its lead janus-associated
kinase (JAK) inhibitor, that is being presented at the upcoming
American Society of Hematology 49th Annual Meeting. The webcast is
scheduled to begin at 7:15 p.m. ET on Monday, December 10, 2007.
The discussion will feature Srdan Verstovsek, M.D., Ph.D.,
Associate Professor Leukemia Department... |
| | | November 20, 2007 | Incyte to Present at the Piper Jaffray 19th Annual Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 20, 2007--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the Piper
Jaffray 19th Annual Health Care Conference on Tuesday, November 27,
2007 at 10:00 a.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.inc... |
| | | November 01, 2007 | Incyte Reviews Positive Proof-of-Concept Clinical Results Achieved During the Third Quarter; Cites Continued Progress in Multiple Drug Development Programs; Announces Third Quarter Financial Results| WILMINGTON, Del., Nov 01, 2007 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) today reviewed its drug discovery
and development programs and reported third quarter 2007 financial
results.
Paul A. Friedman, M.D., President and CEO of Incyte, stated, "We
made significant progress during the third quarter and have now
demonstrated clinical proof-of-concept in four of our wholly owned,
internally developed programs: our CCR5 antagonist for HIV, our JAK
inhibitor for myelofibrosis and pso... |
| | | October 11, 2007 | Incyte to Report Third Quarter 2007 Financial Results and Provide Update on Drug Discovery & Development Programs on November 1| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 11, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
third quarter 2007 financial results conference call for 8:30 a.m. ET
on Thursday, November 1, 2007. The schedules for the press release and
conference call are as follows:
-- Q3 2007 Press Release: November 1, 2007 at 7:00 a.m. ET
-- Q3 2007 Conference Call: November 1, 2007 at 8:30 a.m. ET
-- Domestic Dial In Number: 877-407-8037... |
| | | October 10, 2007 | Incyte Receives $10 million from the Sale of a Convertible Subordinated Note to Pfizer with the Filing and Acceptance of an IND for INCB8696, Its Lead CCR2 Antagonist| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 10, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that, in accordance with the
collaborative research and license agreement with Pfizer Inc. and as a
result of the filing and acceptance of an Investigational New Drug
Application (IND) for INCB8696, Incyte has received $10 million from
the sale of a Convertible Subordinated Note to Pfizer. The Note bears
no interest and is convertible into Incyte common stock at $9.75 per
share based on ... |
| | | September 25, 2007 | Incyte Reports Positive Proof-of-Concept Results For INCB18424, Its Lead JAK Inhibitor, and INCB13739, its Lead 11beta-HSD1 Inhibitor|
A Live and Archived Copy of the Presentation Is Being Made at the
2007 UBS Global Life Sciences Conference and Will Be Available on
Incyte's Website Today, September 25, 2007, Beginning at 4:30 pm ET
WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 25, 2007--Today, at the
2007 UBS Global Life Sciences Conference, Incyte Corporation
(Nasdaq:INCY) will announce positive proof-of-concept clinical results
from the following trials:
a completed 28-day dose-escalation Phase Ib/... |
| | | September 18, 2007 | Data Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent Pharmacokinetics Suitable for Once-Daily Dosing| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 18, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that four scientific posters
have been presented at the 47th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in
Chicago, Illinois.
INCB9471 is a novel, orally available CCR5 antagonist that is a
member of a new class of drugs to treat HIV/AIDS. Data presented at
ICAAC suggest that INCB9471:
is a potent and highly selective i... |
| | | September 17, 2007 | Incyte to Present at the 2007 UBS Global Life Sciences Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 17, 2007--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the 2007
UBS Global Life Sciences Conference on Tuesday, September 25, 2007 at
4:30 p.m. (Eastern Time).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com... |
| | | July 26, 2007 | Incyte Cites Encouraging Clinical Data in Multiple Programs; Announces Second Quarter 2007 Financial Results| Conference Call and Webcast Scheduled for 8:30 a.m. ET Today
WILMINGTON, Del.--(BUSINESS WIRE)--July 26, 2007--Incyte
Corporation (Nasdaq:INCY) today provided a review of the Company's
recent progress for its lead drug discovery and development programs
in HIV, oncology, diabetes and inflammation and reported second
quarter 2007 financial results.
Paul A. Friedman, Incyte's President and Chief Executive Officer
stated, "We're seeing quite encouraging early clinical data in our... |
| | | July 24, 2007 | Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients| Results Suggest that INCB9471 Has the Potential to Provide Advantages over Other CCR5 Antagonists in DevelopmentSYDNEY, Australia, Jul 24, 2007 (BUSINESS WIRE) -- Results from a 14-day Phase IIa clinical trial, presented today at
the 4th International AIDS Society Conference on HIV Pathogenesis,
Treatment and Prevention, demonstrate that INCB9471, an
investigational drug for the treatment of HIV-1, the retrovirus that
causes the acquired immunodeficiency syndrome, AIDS, provided a
significa... |
| | | July 09, 2007 | Incyte to Report Second Quarter 2007 Financial Results and Provide Update on Drug Discovery & Development Programs on July 26| WILMINGTON, Del.--(BUSINESS WIRE)--July 9, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
second quarter 2007 financial results conference call for 8:30 a.m. ET
on Thursday, July 26, 2007. The schedules for the press release and
conference call are as follows:
- Q2 2007 Press Release: July 26, 2007 at 7:00 a.m. ET
- Q2 2007 Conference Call: July 26, 2007 at 8:30 a.m. ET
- Domestic Dial In Number: 877-407-8037
- Internatio... |
| | | June 04, 2007 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--June 4, 2007--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences:
Goldman Sachs Twenty-Eighth Annual Global Healthcare
Conference on Tuesday, June 12, 2007 at 4:00 p.m. (PT) / 7:00
p.m. (ET) in Dana Point, California;
Piper Jaffray Second Annual London Health Care Conference on
Thursday, June 21, 2007 at 8:20 a.m. (BST) in London; and
Jefferies Healthcare... |
| | | May 17, 2007 | Incyte to Present at Upcoming Investment Conferences| WILMINGTON, Del., May 17, 2007 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present
at the 6th Annual JMP Securities Research Conference on Wednesday, May
23, 2007 at 8:30 a.m. (Pacific Time)/11:30 a.m. (Eastern Time) and the
Banc of America Healthcare Conference on Wednesday, May 30, 2007 at
2:00 p.m. (Pacific Time) / 5:00 p.m. (Eastern Time).
The presentations will be webcast live and can be accessed at
www.incyte.com under Investor Relations, Events and We... |
| | | May 03, 2007 | Incyte Reviews Progress in Multiple Drug Development Programs and Announces First Quarter 2007 Financial Results| Conference Call and Webcast Scheduled for 8:30 a.m. ET Today
WILMINGTON, Del.--(BUSINESS WIRE)--May 3, 2007--Incyte Corporation
(NASDAQ:INCY) today announced recent progress in its clinical
development programs for HIV, diabetes, oncology and inflammation and
reported its first quarter 2007 financial results.
Paul Friedman, M.D., Incyte's President and Chief Executive
Officer, stated, "We remain on track to deliver clinical trial results
from several of our programs this year,... |
| | | April 23, 2007 | Incyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference| WILMINGTON, Del.--(BUSINESS WIRE)--April 23, 2007--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
Morgan Stanley Global Healthcare Unplugged Conference on Friday, May
4, 2007 at 11:45 a.m. (Eastern Time). John Keller, PhD, executive vice
president and chief business officer of Incyte, will describe recent
progress in the Company's most advanced drug discovery and development
programs.
The presentation will be webcast live and can be accessed at
www.incyte... |
| | | April 18, 2007 | Incyte to Report First Quarter 2007 Financial Results and Provide Update on Drug Discovery & Development Programs on May 3| WILMINGTON, Del.--(BUSINESS WIRE)--April 18, 2007--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
first quarter 2007 financial results conference call for 8:30 a.m. ET
on Thursday, May 3, 2007. The schedules for the press release and
conference call are as follows:
-- Q1 2007 Press Release: May 3, 2007 at 7:00 a.m. ET
-- Q1 2007 Conference Call: May 3, 2007 at 8:30 a.m. ET
-- Domestic Dial In Number: 877-407-8037
-- Internat... |
| | | February 15, 2007 | Incyte Reviews Recent Progress in Multiple Programs; Announces 2006 Financial Results and 2007 Financial Guidance| Conference Call and Webcast Scheduled for 8:30 a.m. ET Today
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 15, 2007--Incyte
Corporation (Nasdaq:INCY) today reviewed the Company's recent progress
and 2007 objectives for its drug discovery and development programs in
HIV, diabetes, inflammation and oncology, and announced its 2006
financial results and 2007 financial guidance.
Paul A. Friedman, Incyte's President and Chief Executive Officer
stated, "We have made a great deal of progre... |
| | | January 24, 2007 | Incyte to Report 2006 Financial Results and 2007 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 15| WILMINGTON, Del., Jan 24, 2007 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today that it has
scheduled its fourth quarter and year-end 2006 financial results
conference call for 8:30 a.m. ET on Thursday, February 15, 2007. The
schedules for the press release and conference call are as follows:
Q4 & YE 2006 Press Release:
February 15, 2007 at 7:00 a.m. ET
Q4 & YE 2006 Conference Call:
February 15, 2007 at 8:30 a.m. ET
Domestic Dial In Number:
... |
| | | January 08, 2007 | Incyte to Report Positive Preliminary Clinical Results from HIV and Diabetes Programs and Highlight Progress in Several Drug Development Programs at the 25th JPMorgan Healthcare Conference| A Live and Archived Copy of the Presentation Will Be Available on Incyte's Website on January 8, 2007, Beginning at 8:30 am PT/11:30 am ETWILMINGTON, Del., Jan 08, 2007 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) will announce today at the 25th
Annual JPMorgan Healthcare Conference positive preliminary results
from a Phase IIa placebo-controlled trial designed to evaluate the
anti-viral effects and safety of INCB9471, Incyte's lead CCR5
antagonist that is being developed as a once-a... |
| | | January 04, 2007 | Incyte to Present at the 25th Annual JP Morgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 4, 2007--Incyte
Corporation (Nasdaq: INCY) announced today it will present at the 25th
Annual JP Morgan Healthcare Conference on Monday, January 8, 2007 at
11:30 a.m. (Eastern Time) / 8:30 a.m. (Pacific Time). Paul Friedman,
M.D., president and chief executive officer of Incyte, will describe
recent progress in the company's most advanced drug discovery and
development programs and outline key objectives for 2007.
The presentation will be we... |
| | | December 08, 2006 | Registration Statement Declared Effective for the Resale of Incyte's 3 1/2% Convertible Senior Notes Originally Issued in September 2006| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 8, 2006--Incyte
Corporation (Nasdaq:INCY) today announced that the Securities and
Exchange Commission has declared effective its registration statement
on Form S-3 relating to the resale of $151.8 million principal amount
of its 3 1/2% Convertible Senior Notes due 2011 and the shares of its
common stock issuable upon conversion of the notes. The notes were
originally issued in a private placement in September, 2006. Incyte
will not receive any p... |
| | | November 27, 2006 | Incyte to Present at 18th Annual Piper Jaffray Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 27, 2006--Incyte
Corporation (Nasdaq:INCY) announced today that its presentation at the
18th Annual Piper Jaffray Health Care Conference will be webcast live
on Thursday, November 30, 2006 at 12:00 p.m. Eastern Time and can be
accessed at www.incyte.com under Investor Relations, Events and
Webcasts.
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced dru... |
| | | November 21, 2006 | Incyte Announces Filing of Registration Statement for Resale of 3 1/2% Convertible Senior Notes due 2011| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 21, 2006--Incyte
Corporation (Nasdaq:INCY) today announced that it has filed a
registration statement on Form S-3 with the Securities and Exchange
Commission relating to the resale of $151.8 million principal amount
of its 3 1/2% Convertible Senior Notes due 2011 and the shares of its
common stock issuable upon conversion of the notes. The notes were
originally issued in a private placement in September 2006, and the
registration statement is be... |
| | | November 13, 2006 | Incyte to Present at JMP Securities Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 13, 2006--Incyte
Corporation (Nasdaq:INCY) announced today that its presentation at the
JMP Securities Healthcare Conference will be webcast live on Thursday,
November 16, 2006 at 10:30 a.m. Eastern Time and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts.
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery a... |
| | | November 02, 2006 | Incyte Reports Continued Progress in Multiple Drug Discovery and Development Programs; Announces Third Quarter Financial Results| Conference Call and Webcast Scheduled for 8:30 a.m. ET Today
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 2, 2006--Incyte
Corporation (Nasdaq:INCY) today announced its financial results for
the third quarter 2006 and confirmed that it remains on track to
demonstrate potential 'proof-of-concept' in a number of its most
advanced internally developed drug discovery and development programs.
Recent developments include:
Completion of a double-blind, placebo-controlled Phase I s... |
| | | October 20, 2006 | Incyte to Report Third Quarter 2006 Financial Results and Provide Update on Drug Discovery & Development Programs on November 2| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 20, 2006--Incyte
Corporation (Nasdaq: INCY) announced today that it has scheduled its
third quarter 2006 financial results conference call for 8:30 a.m. ET
on Thursday, November 2, 2006. The schedules for the press release and
conference call are as follows:
Q3 2006 Press Release: November 2, 2006 at 7:00 a.m. ET
Q3 2006 Conference Call: November 2, 2006 at 8:30 a.m. ET
Domestic Dial In Number: 877-407-8037
International... |
| | | September 26, 2006 | Incyte Completes Note Offering and Announces Redemption of Outstanding 5.5% Convertible Subordinated Notes Due 2007| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 26, 2006--Incyte
Corporation (Nasdaq:INCY) today announced that it has completed its
previously announced private placement of $151.8 million aggregate
principal amount of 3 1/2% Convertible Senior Notes due 2011,
including the exercise of the initial purchaser's option. Incyte
estimates that the net proceeds from this offering will be
approximately $110.9 million (after deducting fees and expenses).
As previously announced, Incyte will use... |
| | | September 21, 2006 | Incyte to Present at UBS Global Life Sciences Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 21, 2006--Incyte
Corporation (Nasdaq:INCY) announced today its presentation at the UBS
Global Life Sciences Conference will be webcast live on Tuesday,
September 26, 2006 at 4:30 p.m. Eastern Time and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts.
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and dev... |
| | | September 20, 2006 | Incyte Announces Offering of Convertible Senior Notes; Net Proceeds to Be Used to Redeem Its Outstanding 5.5% Convertible Subordinated Notes Due February 1, 2007| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 20, 2006--Incyte
Corporation (Nasdaq: INCY) today announced the offering of
approximately $132 million aggregate principal amount of 3 1/2%
Convertible Senior Notes due 2011 in a private placement pursuant to
exemptions from the registration requirements of the Securities Act of
1933. Incyte intends to use the net proceeds of this offering,
estimated to be at least $96 million (after deducting fees and
expenses), to redeem its outstanding 5.5% ... |
| | | August 29, 2006 | Incyte to Present at Thomas Weisel Partners Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 29, 2006--Incyte
Corporation (Nasdaq:INCY) announced today its presentation at the
Thomas Weisel Partners Healthcare Conference will be webcast live on
Wednesday, September 6, 2006 at 2:05 p.m. Eastern Time and can be
accessed at www.incyte.com under Investor Relations, Events and
Webcasts.
John Keller, Ph.D., executive vice president and chief business
officer of Incyte, will provide an overview of the company and discuss
its most advanced... |
| | | July 27, 2006 | Incyte Announces Second Quarter Financial Results; Provides Update on Drug Discovery and Development Programs; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today| WILMINGTON, Del.--(BUSINESS WIRE)--July 27, 2006--Incyte
Corporation (Nasdaq:INCY) today announced its financial results for
the second quarter 2006 and reported on the Company's most advanced
drug discovery and development programs.
Recent developments include:
Initiation of Phase I testing in healthy volunteers of an
internally developed oral CCR5 antagonist, INCB9471, for
treatment of HIV.
Initiation of Phase I testing in healthy volunteers of... |
| | | July 10, 2006 | Incyte to Report Second Quarter 2006 Financial Results; Provide Update on Drug Discovery & Development Programs on July 27| WILMINGTON, Del.--(BUSINESS WIRE)--July 10, 2006--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
second quarter 2006 financial results conference call for 8:30 a.m. ET
on Thursday, July 27, 2006. The schedules for the press release and
conference call are as follows:
Q2 2006 Press Release: July 27, 2006 at 7:00 a.m. ET
Q2 2006 Conference Call: July 27, 2006 at 8:30 a.m. ET
Domestic Dial In Number: 877-692-2592
... |
| | | June 22, 2006 | Incyte Invites Investors to Listen to Webcast of Presentation at the Jefferies Life Sciences Conference| WILMINGTON, Del.--(BUSINESS WIRE)--June 22, 2006--Incyte
Corporation (Nasdaq:INCY) announced today its presentation at the
Jefferies Life Sciences Conference will be webcast live on Tuesday,
June 27, 2006 at 1:15 p.m. Eastern Time and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts.
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and developmen... |
| | | June 07, 2006 | Incyte Begins Phase I Study of INCB13739 as a New Treatment for Type 2 Diabetes| WILMINGTON, Del.--(BUSINESS WIRE)--June 7, 2006--Incyte
Corporation (Nasdaq:INCY) today announced that it has initiated a
Phase I clinical trial of INCB13739, an orally available small
molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid
dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be
critical to the development of type 2 diabetes.
11beta-HSD1 converts inactive cortisone into the active
glucocorticoid, cortisol, a natural antagonist of insulin action.
Huma... |
| | | June 06, 2006 | Incyte to Present at Needham Conference| WILMINGTON, Del.--(BUSINESS WIRE)--June 6, 2006--Incyte
Corporation (Nasdaq:INCY) announced today it is scheduled to present
at the Fifth Annual Needham Biotechnology and Medical Technology
Conference, on Wednesday, June 14, 2006 at 4:30 p.m. in New York City
(ET).
Paul Friedman, M.D., president and chief executive officer of
Incyte, will provide an overview of the company and discuss its most
advanced drug discovery and development programs.
The presentations will be webcast... |
| | | May 23, 2006 | Incyte Stockholders Elect Two New Directors| WILMINGTON, Del.--(BUSINESS WIRE)--May 23, 2006--Incyte
Corporation (Nasdaq:INCY) today announced that stockholders
representing 77 percent of the company's outstanding shares re-elected
six current directors and elected two new directors at the company's
2006 annual meeting. The two new directors are John Niblack, Ph.D.,
former Pfizer Inc Vice Chairman and President of Global Research and
Development, and Matthew Emmens, Chief Executive Officer of Shire plc,
a global specialty pharma... |
| | | May 10, 2006 | Incyte Begins Phase I Study of New HIV Drug in Healthy Volunteers| WILMINGTON, Del.--(BUSINESS WIRE)--May 10, 2006--Incyte
Corporation (Nasdaq:INCY) today announced that it has initiated a
Phase I clinical trial of INCB9471, a new orally available CCR5
antagonist that is being developed as a treatment for patients
infected with human immunodeficiency virus (HIV-1), the retrovirus
that causes acquired immune deficiency syndrome. CCR5 antagonists are
a new class of antiretroviral compounds that have been shown to block
entry of the HIV virus into the c... |
| | | May 08, 2006 | Incyte Invites Investors to Listen to Webcast of Presentation at the Bank of America 2006 Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--May 8, 2006--Incyte Corporation
(Nasdaq:INCY) announced today its presentation at the Bank of America
2006 Health Care Conference will be webcast live on Tuesday, May 16,
2006 at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) and can be
accessed at www.incyte.com under Investor Relations, Events and
Webcasts.
Investors interested in listening to the live webcast should log
on before the start time in order to download any software required.
Th... |
| | | May 04, 2006 | Incyte Announces First Quarter Financial Results and Provides Update on Drug Discovery and Development Programs; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today| WILMINGTON, Del.--(BUSINESS WIRE)--May 4, 2006--Incyte Corporation
(Nasdaq:INCY) today announced its financial results for the first
quarter 2006 and reported on the company's most advanced drug
discovery and development programs.
Recent developments include:
The decision to discontinue development of our lead HIV
compound, DFC (dexelvucitabine, formerly Reverset) because of
an unacceptably high increase in the frequency of grade 4
hyperlipasemia in ... |
| | | April 24, 2006 | Incyte Invites Investors to Listen to Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference| WILMINGTON, Del.--(BUSINESS WIRE)--April 24, 2006--Incyte
Corporation (Nasdaq:INCY) announced today its presentation at the
Morgan Stanley Global Healthcare Unplugged Conference will be webcast
live on Thursday, May 4, 2006 at 4:30 p.m. Eastern Time (1:30 p.m.
Pacific Time) and can be accessed at www.incyte.com under Investor
Relations, Events and Webcasts.
Investors interested in listening to the live webcast should log
on before the start time in order to download any software... |
| | | April 21, 2006 | Incyte to Report First Quarter 2006 Financial Results; Provide Update on Drug Discovery & Development Programs on May 4| WILMINGTON, Del.--(BUSINESS WIRE)--April 21, 2006--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
first quarter 2006 financial results conference call for 8:30 a.m. ET
on Thursday, May 4, 2006. The schedules for the press release and
conference call are as follows:
Q1 2006 Press Release: May 4, 2006 at 7:00 a.m. ET
Q1 2006 Conference Call: May 4, 2006 at 8:30 a.m. ET
Domestic Dial In Number: 877-69... |
| | | April 03, 2006 | Incyte to Discontinue Development of DFC as a Treatment for HIV; Conference Call Scheduled for 8:30 a.m. ET Today| WILMINGTON, Del., Apr 03, 2006 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) announced today its
decision to discontinue the development of DFC (formerly Reverset),
due to a recently observed increase in the frequency of grade 4
hyperlipasemia in patients receiving 200 mg DFC without 3TC or FTC.
The increased incidence of grade 4 hyperlipasemia was observed in
Study 901, the long-term extension of Incyte's first Phase IIb trial
(Study 203). Hyperlipasemia is a marker of pancreatic i... |
| | | February 21, 2006 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 21, 2006--Incyte
Corporation (Nasdaq:INCY) announced today it is scheduled to present
at the following investor conferences:
Fifth Annual JMP Securities Research Conference on Tuesday,
March 7, 2006 at 3:50 p.m. in San Francisco (PT); and
Lehman Brothers Ninth Annual Global Heathcare Conference on
Thursday, March 9, 2006 at 3:45 p.m. in Miami Beach (ET).
The presentations will be webcast live and can be access... |
| | | February 16, 2006 | Incyte Announces 2005 Financial Results and Provides 2006 Guidance; Initiates Study 204 for DFC in Treatment-Experienced HIV Patients and Receives $50 Million from CCR2 Alliance with Pfizer| Conference Call and Webcast Scheduled for 8:30 a.m. ET TodayWILMINGTON, Del., Feb 16, 2006 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) today announced 2005 financial
results and 2006 financial guidance, and reported on the company's
most advanced drug discovery and development programs including
dexelvucitabine, or DFC, our Phase II compound for human immune
deficiency virus (HIV).
Recent accomplishments include:
Initiation of Study 204, a six-month Phase IIb trial designed
... |
| | | January 25, 2006 | Incyte to Report 2005 Financial Results and 2006 Financial Guidance; Provide Update on Drug Discovery & Development Programs on February 16| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 25, 2006--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
fourth quarter and year-end 2005 financial results conference call for
8:30 a.m. ET on Thursday, February 16, 2006. The schedules for the
press release and conference call are as follows:
Q4 & YE 2005 Press Release: February 16, 2006 at 7:00 a.m. ET
Q4 & YE 2005 Conference Call: February 16, 2006 at 8:30 a.m.
ET
Domestic Dial In Numb... |
| | | January 05, 2006 | Incyte to Present at the 24th Annual JPMorgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 5, 2006--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the 24th
Annual JPMorgan Healthcare Conference on Thursday, January 12, 2006 at
10:00 a.m. (PT). Paul Friedman, M.D., president and chief executive
officer of Incyte, will provide an overview of the company and discuss
its most advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com under Investor... |
| | | November 21, 2005 | Incyte to Host Conference Call Today to Discuss Collaborative Research and License Agreement with Pfizer for the Development and Commercialization of CCR2 Antagonists; Conference Call is Scheduled to Begin at 8:30 a.m. ET Today| WILMINGTON, Del., Nov 21, 2005 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced that it will
host a conference call at 8:30 am ET today to discuss its
collaborative research and license agreement with Pfizer for the
development and commercialization of CCR2 antagonists. A copy of the
press release, also released today, can be accessed at www.incyte.com.
The schedule and dial in information for the conference call are
as follows:
-- Conference Call: Novemb... |
| | | November 21, 2005 | Pfizer and Incyte Enter Collaborative Research and License Agreement for the Development and Commercialization of CCR2 Antagonists| NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 21,
2005--Incyte Corporation (NASDAQ:INCY):
Pfizer Gains Worldwide Development and Commercialization
Rights Across a Broad Range of Indications
Incyte May Receive Up to $803 Million in Payments and Retains Rights
in Multiple Sclerosis and an Additional Undisclosed Indication
Pfizer Inc (NYSE:PFE) and Incyte Corporation (NASDAQ:INCY)
announced today that the two companies have entered into a global... |
| | | November 01, 2005 | Incyte Announces Third Quarter 2005 Results; Provides Update on Most Advanced Drug Development Programs and Reduces Cash Use Guidance for 2005; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2005--Incyte
Corporation (Nasdaq:INCY) today announced its third quarter 2005
financial results, revised its 2005 financial guidance and updated
shareholders on recent developments, including:
Incyte's decision to initiate, at the request of the U.S. Food
and Drug Administration (FDA), a second Phase IIb trial for
Reverset prior to beginning the pivotal Phase III program;
Progression of two Phase IIa trials in r... |
| | | October 19, 2005 | Incyte to Report Third Quarter 2005 Financial Results on November 1| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 19, 2005--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
third quarter 2005 financial results conference call for 8:30 a.m. ET
on Tuesday, November 1, 2005. The schedules for the press release and
conference call are as follows:
Q3/2005 Press Release: November 1, 2005 at 7:00 a.m. ET
Q3/2005 Conference Call: November 1, 2005 at 8:30 a.m. ET
Domestic Dial In Number: 877-692-2592
Intern... |
| | | September 28, 2005 | Incyte Announces Outcome of Discussions with FDA Regarding Reverset(TM)| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 28, 2005--Incyte
Corporation (NASDAQ:INCY) announced today that it met with
representatives from the FDA yesterday regarding the development of
Reverset, Incyte's nucleoside reverse transcriptase inhibitor (NRTI)
that is being developed as a therapy for treatment-experienced HIV
patients.
The purpose of the meeting was to discuss the results of a
recently completed Phase II trial, which were presented in July at the
IAS meeting, and the co... |
| | | August 31, 2005 | Incyte to Present at Investor Conferences in September| WILMINGTON, Del., Aug 31, 2005 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it is
scheduled to present at the following investor conferences:
Thomas Weisel Partners Healthcare Tailwinds 2005 Conference on
Wednesday, September 7, 2005 at 3:15 p.m. in Boston (ET);
Bear Stearns 18th Annual Healthcare Conference on Monday,
September 12, 2005 at 11:00 a.m. in New York City (ET); and
2005 UBS Global Life Sciences Conference, on Wednesday,
... |
| | | August 01, 2005 | Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients| WILMINGTON, Del., Aug 01, 2005 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced its second
quarter 2005 financial results and reported on recent achievements
including:
Presentation of positive Phase IIb results for Reverset at the
3rd International AIDS Society Conference in Rio De Janeiro;
Initiation of a second Phase IIa trial in obese
insulin-resistant patients for INCB3284, Incyte's
orally-available CCR2 antagonist; and
Completio... |
| | | July 25, 2005 | Incyte to Report Second Quarter 2005 Financial Results on August 1, Update Investors at Meeting in New York on August 2| WILMINGTON, Del.--(BUSINESS WIRE)--July 25, 2005--Incyte
Corporation (Nasdaq:INCY) announced today that it will report its
second quarter 2005 financial results at 5:00 p.m. ET on Monday,
August 1, 2005.
On Tuesday morning, August 2, 2005, Incyte will host an investor
meeting at the St. Regis Hotel in New York City to discuss the results
of the Reverset(TM) Phase IIb study that were presented today at the
3rd International AIDS Society Conference and to review second quarter
financ... |
| | | July 25, 2005 | Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity in Treatment-Experienced HIV Patients Failing Current Treatment Regimen; Findings Presented at the 3rd International AIDS Society Conference| RIO DE JANEIRO, Brazil--(BUSINESS WIRE)--July 25, 2005--Incyte
Corporation (Nasdaq:INCY) today announced positive results from Study
203, a six-month randomized double-blind Phase IIb trial, involving
199 patients and 25 clinical sites in the U.S. and Europe to evaluate
the efficacy, dose response, safety and tolerability of Reverset in
treatment-experienced human immunodeficiency virus (HIV) infected
patients who are failing their current treatment regimens. Results
from the first two st... |
| | | July 07, 2005 | Results from Reverset Study 203 Accepted for Late Breaker Presentations at 3rd International AIDS Society Conference in Rio de Janeiro|
WILMINGTON, Del.--(BUSINESS WIRE)--July 7, 2005--
Antiretroviral Activity and Tolerability of Reverset(TM) (D-d4FC)
Demonstrated with Combination Therapy in Treatment-Experienced
Patients
Incyte Corporation (Nasdaq:INCY) today announced that an abstract
describing results from the Phase IIb study of Reverset has been
accepted for both oral and poster presentations at the late breaker
sessions of the 3rd International AIDS Society (IAS)... |
| | | May 31, 2005 | Incyte Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference| Incyte Corporation (Nasdaq:INCY) announced today it will
present at the Goldman Sachs 26th Annual Global Healthcare Conference
on Tuesday, June 14, 2005 at 2:40 p.m. (PT). Paul Friedman, M.D.,
president and chief executive officer of Incyte, will provide an
overview of the company and discuss its most advanced drug discovery
and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts.
Investors in... |
| | | May 04, 2005 | Incyte Announces First Quarter 2005 Results; Progress Achieved in Top Three Drug Development Programs; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today| WILMINGTON, Del., May 04, 2005 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) today announced its
first quarter 2005 financial results and reported on the company's
most advanced drug discovery and development programs including
Reverset(TM), its Phase II compound for human immune deficiency virus
(HIV), INCB3284, its CCR2 antagonist for inflammation, and INCB7839,
its sheddase inhibitor for cancer.
Recent accomplishments include:
-- Completion of enrollment for Study 203, t... |
| | | April 27, 2005 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--April 27, 2005--Incyte
Corporation (Nasdaq:INCY) announced today it is scheduled to present
at the following investor conferences:
-- Morgan Stanley Third Annual Global Healthcare Unplugged
Conference 2005 on Thursday, May 5, 2005 at 11:15 a.m. (ET) in
Miami;
-- Banc of America Securities Health Care Conference on Tuesday,
May 17, 2005 at 3:20 p.m. (PT) in Las Vegas; and
-- Needham & Company Fourth Annual B... |
| | | April 11, 2005 | Incyte to Report First Quarter 2005 Financial Results
on May 4| WILMINGTON, Del., Apr 11, 2005 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today that it
has scheduled its first quarter 2005 financial results conference call
for 8:30 a.m. EDT on Wednesday, May 4, 2005. The schedules for the
press release and conference call are as follows:
Q1/2005 Press Release: May 4, 2005 at 7:00 a.m. EDT
Q1/2005 Conference Call: May 4, 2005 at 8:30 a.m. EDT
Domestic Dial In Number: 877-692-2592
International Dial In Numbe... |
| | | April 06, 2005 | Incyte Begins Phase I Study in Healthy Volunteers of Novel Oral Cancer Compound, INCB7839| WILMINGTON, Del.--(BUSINESS WIRE)--April 6, 2005--Incyte
Corporation (Nasdaq:INCY) today announced that it has initiated a
Phase I clinical trial of INCB7839, a novel orally-available sheddase
inhibitor that is being developed as a treatment for solid tumors.
Sheddase is an enzymatic activity attributed to the ADAM (a
disintegrin and metalloprotease) family of proteins that has been
shown to play a role in controlling the growth and spread of certain
cancers that are regulated by members ... |
| | | March 24, 2005 | Incyte to Present at Lehman and BioCentury
Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--March 24, 2005--Incyte
Corporation (Nasdaq:INCY) announced today it is scheduled to present
at the following investor conferences:
Lehman Brothers Global Healthcare Conference on Wednesday,
March 30, 2005 at 2:30 p.m. (ET) in Miami
BioCentury / Thomson Future Leaders in the Biotech Industry on
Thursday, April 7, 2005 at 3:50 p.m. (ET) in New York City
John Keller, Ph.D., executive vice president and chief busine... |
| | | February 28, 2005 | Incyte Provides Update on Most Advanced Discovery and Development Programs; Announces 2004 Financial Results and Provides 2005 Guidance|
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 28, 2005--
Conference Call and Webcast Scheduled for 4:30 p.m. ET Today
Incyte Corporation (Nasdaq:INCY) today announced 2004 financial
results and 2005 financial guidance and reported on the company's most
advanced drug discovery and development programs including
Reverset(TM), its Phase II compound for human immune deficiency virus
(HIV), INCB3284, its CCR2 antagonist for inflammation, and INCB7839,
its sheddase inhibitor for ... |
| | | February 22, 2005 | Incyte to Present at Several Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 22, 2005--Incyte
Corporation (Nasdaq:INCY) announced today it is scheduled to present
at the following investor conferences:
-- SunTrust Robinson Humphrey's Therapeutics Conference on
Tuesday, March 1, 2005 at 1:45 p.m. in New York City (ET)
-- Wells Fargo Securities 2005 Healthcare Conference on
Wednesday, March 2, 2005 at 2:15 p.m. in New York City (ET)
-- JMP Securities Research Conference on Wednesday, Marc... |
| | | February 09, 2005 | Incyte to Report 2004 Financial Results and 2005 Financial Guidance; Provide Update on Discovery & Development Programs on February 28| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 9, 2005--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
fourth quarter and year-end 2004 financial results conference call for
4:30 p.m. EST on Monday, February 28, 2005. The schedules for the
press release and conference call are as follows:
Q4 & YE 2004 Press Release: February 28, 2005 at 4:05 p.m. EST
Q4 & YE 2004 Conference Call: February 28, 2005 at 4:30 p.m. EST
Domestic Dial In Number: 87... |
| | | January 20, 2005 | Incyte to Present at the Piper Jaffray Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 20, 2005--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the Piper
Jaffray Health Care Conference on Wednesday, January 26, 2005 at 10:30
a.m. (ET). Paul Friedman, M.D., president and chief executive officer
of Incyte, will provide an overview of the company and discuss its
most advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com under Investor Relat... |
| | | January 18, 2005 | BIOBASE Acquires the Proteome Subsidiary of Incyte| BIOBASE Acquires the Proteome Subsidiary of Incyte... |
| | | January 07, 2005 | Incyte to Present at the 23rd Annual JPMorgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 7, 2005--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the 23rd
Annual JPMorgan Healthcare Conference on Thursday, January 13, 2005 at
9:30 a.m. (PT). Paul Friedman, M.D., president and chief executive
officer of Incyte, will provide an overview of the company and discuss
its most advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at
www.incyte.com under Investor Re... |
| | | November 19, 2004 | Incyte to Participate in the Punk, Ziegel & Company Investor Symposium on New Agents to Treat HIV| WILMINGTON, Del., Nov 19, 2004 (BUSINESS WIRE) -- Incyte
Corporation (Nasdaq:INCY) announced today that Richard Levy, M.D.,
senior vice president, drug development of Incyte will present at the
Punk, Ziegel & Company's Investor Symposium, New Agents to Treat HIV,
on Monday, November 22, 2004 at 10:50 a.m. (ET).
The presentation will be webcast live and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts. A replay
of the presentation will be available until ... |
| | | November 04, 2004 | Incyte Announces Third Quarter Financial Results; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 4, 2004--Incyte
Corporation (Nasdaq:INCY) announced today its financial results for
the third quarter ended September 30, 2004 and reported on its drug
discovery and development programs in the treatment of human immune
deficiency virus (HIV) infection, inflammation and cancer.
Recent accomplishments include:
Repurchase of $38.4M of its 5.5% convertible subordinated
notes
Announcement of a public offering of 9 m... |
| | | November 01, 2004 | Incyte Announces Pricing of Common Stock Offering| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2004--Incyte
Corporation (Nasdaq:INCY) today announced that it has agreed to sell 9
million shares of its common stock, at a price to the public of $9.75
per share, pursuant to Incyte's effective shelf registration
statement. Morgan Stanley & Co. Incorporated is acting as the sole
underwriter for the offering. Incyte has granted the underwriter a
30-day option to purchase up to 1.35 million additional shares of its
common stock to cover over-allo... |
| | | November 01, 2004 | Incyte Commences Public Offering of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2004--Incyte
Corporation (Nasdaq:INCY) today announced that it is offering 9
million shares of its common stock, pursuant to Incyte's effective
shelf registration statement. Morgan Stanley & Co. Incorporated is
acting as the sole underwriter for the offering. Incyte intends to
grant the underwriter a 30-day option to purchase up to 1.35 million
additional shares of its common stock to cover over-allotments, if
any. Incyte intends to use the net p... |
| | | October 31, 2004 | Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients| WASHINGTON--(BUSINESS WIRE)--Oct. 31, 2004--Incyte
Corporation(NASDAQ:INCY):
Additional analysis of results of a 10 patient 10-day phase
IIa study presented at ICAAC also suggest Reverset is
effective for patients with viral mutations often seen in
treatment with currently available nucleoside-analogue reverse
transcriptase inhibitors
Incyte Corporation (Nasdaq:INCY) announced that patients with HIV
who were failing antiretroviral ther... |
| | | October 28, 2004 | Incyte to Present at the CIBC World Markets Fifteenth Annual Heathcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 28, 2004--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the CIBC
World Markets Fifteenth Annual Healthcare Conference on Tuesday,
November 9, 2004 at 4:00 p.m. (ET). John Keller, Ph.D., executive vice
president and chief business officer of Incyte, will provide an
overview of the company and discuss its most advanced drug discovery
and development programs.
The presentation will be webcast live and can be accessed at
www... |
| | | October 28, 2004 | Incyte to Report Third Quarter 2004 Financial Results on November 4| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 28, 2004--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
third quarter 2004 financial results conference call for 8:30 a.m. EST
on Thursday, November 4, 2004. The schedules for the press release and
conference call are as follows:
Q3/2004 Press Release: November 4, 2004 at 7:00 a.m. EST
Q3/2004 Conference Call: November 4, 2004 at 8:30 a.m. EST
Domestic Dial In Number: 1-877-692-2592
In... |
| | | October 07, 2004 | Incyte Announces Filing of $175 Million Shelf Registration| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 7, 2004--Incyte
Corporation (Nasdaq:INCY) today announced that it has filed a shelf
registration statement on Form S-3 with the Securities and Exchange
Commission (SEC) for the proposed offering, from time to time, of up
to $175 million of Incyte common stock. The company intends to use the
proceeds from any offerings for general corporate purposes, which may
include repayment or redemption of outstanding indebtedness and
funding of clinical trials ... |
| | | September 21, 2004 | Incyte to Present at the 2004 UBS Global Life Sciences Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 21, 2004--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the 2004
UBS Global Life Sciences Conference on Tuesday, September 28, 2004 at
4:30 p.m. (ET). Paul Friedman, M.D., president and chief executive
officer of Incyte, will provide an overview of the company and discuss
its most advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at:
www.incyte.com under Investor ... |
| | | August 26, 2004 | Incyte to Present at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 26, 2004--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
Thomas Weisel Partners Healthcare Tailwinds 2004 Conference on
Wednesday, September 8, 2004 at 10:00 a.m. (ET). John Keller, Ph.D.,
executive vice president and chief business officer of Incyte, will
provide an overview of the company and discuss its most advanced drug
discovery and development programs.
The presentation will be webcast live and can be accessed a... |
| | | August 04, 2004 | Incyte Announces Second Quarter Financial Results; Provides Update on Reverset and INCB3284, Incyte's Phase I CCR2 Antagonist|
WILMINGTON, Del.--Aug. 4, 2004--
Conference Call and Webcast Scheduled for 8:30 a.m. ET Today
Incyte Corporation (Nasdaq:INCY) announced today its financial
results for the second quarter ended June 30, 2004 and updated
shareholders on its most recent corporate accomplishments, including:
Initiation of patient enrollment for a Phase IIb trial using
Reverset(TM) in combination with other antiviral agents
involving 180 treatment-experienced ... |
| | | July 26, 2004 | Incyte to Report Second Quarter 2004 Financial Results| WILMINGTON, Del.--July 26, 2004--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
second quarter 2004 financial results conference call for 8:30 a.m. ET
on Wednesday, August 4, 2004. The schedule for the press release and
conference call are as follows:
Q2/2004 Press Release: August 4, 2004 at 6:00 a.m. ET
Q2/2004 Conference Call: August 4, 2004 at 8:30 a.m. ET
Domestic Dial In Number: 1-877-692-2592
I... |
| | | July 15, 2004 | Incyte Announces Effectiveness of Registration Statement for Resale of 3- 1/2% Convertible Subordinated Notes due 2011| WILMINGTON, Del.--July 15, 2004--Incyte
Corporation (Nasdaq:INCY) today announced that the Securities and
Exchange Commission has declared effective its registration statement
on Form S-3 relating to the resale of $250 million principal amount of
its 3- 1/2 % Convertible Subordinated Notes due 2011 and the shares of
its common stock issuable upon conversion of the notes. The notes were
originally issued in a private placement in February and March, 2004.
Incyte will not receive any procee... |
| | | July 12, 2004 | Results of Phase II Study Presented at the XV International AIDS Conference Demonstrate Reverset Has Potential to Reduce Viral Load in Treatment-Naive and Treatment-Experienced HIV Patients| BANGKOK, Thailand, Jul 12, 2004--Incyte
Corporation (Nasdaq:INCY). Patients with human immunodeficiency virus
(HIV) who were treated for 10 days with Reverset(TM), a
nucleoside-analogue reverse transcriptase inhibitor (NRTI) that is
being developed as a once-a-day oral therapy for use in combination
with other antiretroviral drugs, showed a reduction in viral load
according to the results of a Phase II clinical trial presented today
at the XV International AIDS Conference in Bangkok, Thai... |
| | | June 14, 2004 | Incyte to Present at the Third Annual Needham Biotechnology Conference| WILMINGTON, Del.--(BUSINESS WIRE)-Incyte
Corporation (Nasdaq:INCY) announced today it will present at the Third
Annual Needham Biotechnology Conference on Wednesday, June 16, 2004 at
9:30 a.m. (ET). Paul Friedman, MD., president and chief executive
officer of Incyte, will provide an overview of the company and discuss
its most advanced drug discovery and development programs.
The presentation will be webcast live and can be accessed at:
www.incyte.com/webcasts. A replay of the prese... |
| | | May 25, 2004 | Incyte to Present at the SunTrust Robinson Humphrey 33rd Annual Institutional Conference| WILMINGTON, Del.--May 25, 2004--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
SunTrust Robinson Humphrey 33rd Annual Institutional Conference on
Wednesday, May 26, 2004 at 9:45 a.m. (ET). John Keller, Ph.D.,
executive vice president and chief business officer of Incyte, will
provide an overview of the company and discuss its most advanced drug
discovery and development programs.
The presentation will be webcast live and can be accessed at:
www.incyte.com/w... |
| | | May 18, 2004 | Incyte to Present at the Banc of America Health Care Conference| WILMINGTON, Del., May 18, 2004 -- Incyte
Corporation (Nasdaq:INCY) announced today it will present at the Banc
of America Health Care Conference on Thursday, May 20, 2004 at 2:40
p.m. (PT). Paul Friedman, M.D., chief executive officer of Incyte,
will provide an overview of the company and discuss its most advanced
drug discovery and development programs.
The presentation will be webcast live and can be accessed at:
www.incyte.com/webcasts. A replay of the presentation will be
availab... |
| | | May 11, 2004 | Incyte Initiates Phase I Testing of Oral CCR2 Antagonist; Growing Body of Evidence Suggests CCR2 Antagonists May Have Therapeutic Value in a Number of Chronic Inflammatory Diseases| WILMINGTON, Del.--May 11, 2004--Incyte
Corporation (Nasdaq:INCY) announced today that it has begun a Phase I
study to assess the safety and tolerability of its most advanced oral
CCR2 antagonist, INCB3284, in healthy volunteers. The Phase I trial is
being conducted at one clinical site in the United States and involves
both single and multiple doses of INCB3284.
The multiple dose portion of the trial will also involve a delayed
type hypersensitivity (DTH) test that is intended to se... |
| | | May 07, 2004 | Incyte to Present at the SunTrust Robertson Humphrey Therapeutics Conference| WILMINGTON, Del.--(BUSINESS WIRE)--May 7, 2004--Incyte Corporation
(Nasdaq:INCY) announced today it will present at the SunTrust
Robertson Humphrey "Off The Cuff" Therapeutics Conference on Tuesday,
May 11, 2004 at 1:45 p.m. (EST). Paul Friedman, M.D., chief executive
officer of Incyte, will provide an overview of the company and discuss
its most advanced drug discovery and development programs.
An audio version of the presentation will be webcast live and can
be accessed at: www.in... |
| | | May 04, 2004 | Incyte Announces First Quarter 2004 Financial Results, Provides Update on Most Advanced Drug Discovery and Development Programs|
WILMINGTON, Del.--(BUSINESS WIRE)--May 4, 2004--
Conference Call and Webcast Scheduled for Today at 8:30 a.m. ET
Incyte Corporation (Nasdaq:INCY) announced today its financial
results for the first quarter ended March 31, 2004 and updated
shareholders on its most recent corporate accomplishments, including:
Presentation of positive clinical results from a 10-day Phase
II dose-escalating, placebo-controlled trial designed to
evaluate the antivir... |
| | | April 29, 2004 | Incyte to Present at the Morgan Stanley HealthCare Unplugged Conference| WILMINGTON, Del.--(BUSINESS WIRE)--April 29, 2004--Incyte
Corporation (Nasdaq:INCY) announced today it will present at the
Morgan Stanley HealthCare Unplugged Conference on Wednesday, May 5,
2004 at 1:30 p.m. (EST). Paul Friedman, M.D., chief executive officer
of Incyte, will provide an overview of the company and discuss its
most advanced drug discovery and development programs.
An audio version of the presentation will be webcast live and can
be accessed at: www.incyte.com/webcast... |
| | | April 26, 2004 | Incyte to Report First Quarter 2004 Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--April 26, 2004--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
first quarter 2004 financial results conference call for 8:30 a.m. ET
on Tuesday, May 4, 2004. The schedule for the press release and
conference call are as follows:
Q1/2004 Press Release: May 4, 2004 at 6:00 a.m. ET
Q1/2004 Conference Call: May 4, 2004 at 8:30 a.m. ET
Domestic Dial In Number: 1-877-692-2592
International Dia... |
| | | April 26, 2004 | Incyte Announces Filing of Registration Statement for Resale of 3- 1/2% Convertible Subordinated Notes Due 2011| WILMINGTON, Del.--(BUSINESS WIRE)--April 26, 2004--Incyte
Corporation (Nasdaq:INCY) today announced that it has filed a
registration statement on Form S-3 with the Securities and Exchange
Commission relating to the resale of $250 million principal amount of
its 3- 1/2 % Convertible Subordinated Notes due 2011 and the shares of
its common stock issuable upon conversion of the notes. The notes were
originally issued in a private placement in February and March 2004,
and the registration sta... |
| | | March 08, 2004 | Incyte Completes Sale of an Additional $50 Million of Convertible Subordinated Notes| WILMINGTON, Del., Mar 8, 2004-- Incyte
Corporation (Nasdaq:INCY) today announced that it issued an additional
$50 million of its 3- 1/2 % Convertible Subordinated Notes due 2011
pursuant to the exercise of the option granted to the initial
purchasers of the notes. With this option exercise, Incyte has sold
$250 million aggregate principal amount of notes in a private
placement to qualified institutional buyers.
The notes are convertible into Incyte common stock at an initial
conversi... |
| | | March 01, 2004 | Incyte To Present At Lehman Brothers Seventh Annual Global Healthcare Conference| WILMINGTON, Del.--March 1, 2004--Incyte
Corporation (Nasdaq:INCY) announced today that the company will
present at the Lehman Brothers Seventh Annual Global Healthcare
Conference at 4:45 p.m. (EST) on Wednesday March 3. Paul Friedman,
M.D., chief executive officer of Incyte, will provide an overview of
the company and discuss its most advanced drug discovery and
development programs.
The presentation will be webcast, both live and as replay, through
the Lehman Brothers Global Healt... |
| | | February 12, 2004 | Incyte Prices $200 Million Convertible Subordinated Notes Offering| WILMINGTON, Del.----Feb. 12, 2004--Incyte
Corporation (Nasdaq: INCY) today announced the pricing of its offering
of $200 million of 3-1/2% Convertible Subordinated Notes due 2011 in a
private placement to qualified institutional buyers pursuant to
exemptions from the registration requirements of the Securities Act of
1933. The offering is expected to close on February 19, 2004, subject
to customary closing conditions. Incyte has granted the initial
purchasers of the notes an option to pur... |
| | | February 11, 2004 | Reverset Data Presented at the 11th Annual Conference on Retroviruses and Opportunistic Infections Demonstrate Potent Antiviral Effects in Treatment-Naive HIV Patients| SAN FRANCISCO--(BUSINESS WIRE)--Feb. 11, 2004--Incyte Corporation
(Nasdaq:INCY) and Pharmasset, Inc., its strategic collaborative and
licensing partner for Reverset(TM), announced today the results of a
10-day Phase II dose-escalating, placebo-controlled trial designed to
evaluate the anti-viral effects and safety of Reverset as monotherapy
in 30 treatment-naive human immunodeficiency virus (HIV)-infected
patients. The mean reduction in viral load for all treated patients
ranged from 1.67... |
| | | February 11, 2004 | Incyte Announces Proposed Offering of $150 Million Convertible Subordinated Notes| WILMINGTON, Del.--Feb. 11, 2004--Incyte
Corporation (Nasdaq:INCY) today announced that it intends to offer,
subject to market and other conditions, $150 million of Convertible
Subordinated Notes due 2011 in a private placement to qualified
institutional buyers pursuant to exemptions from the registration
requirements of the Securities Act of 1933. The notes will bear
interest, and will be convertible into shares of Incyte's common stock
at a rate and price to be determined. Incyte expects... |
| | | February 11, 2004 | Incyte to Host Conference Call to Discuss Clinical Results From a Phase II Study of Reverset in HIV-Infected Patients| WILMINGTON, Del.--Feb. 11, 2004--
Call Scheduled For Thursday February 12, 2004 - 8:30 a.m. ET/5:30
a.m. PT
Incyte Corporation (Nasdaq:INCY) announced today that it will host
a conference call on Thursday, February 12, 2004 to discuss the
clinical results from a Phase II study of Reverset(TM) in
treatment-naive human immunodeficiency virus (HIV)-infected patients.
The schedule for the conference call is as follows:
Reverset Conference Call: 8:30 a.m. ET ... |
| | | February 07, 2004 | Incyte and Pharmasset Announce Preliminary Findings from Phase II Study of Reverset in HIV-Infected Patients; Once-Daily Dosing Results in Significant Reduction in Viral Load| WILMINGTON, Del. & ATLANTA, Feb 7, 2004 -- Incyte
Corporation (Nasdaq:INCY) and Pharmasset Inc. announced that
preliminary results of a 10-day Phase II dose-escalating,
placebo-controlled trial designed to evaluate the anti-viral effects
and safety of Reverset(TM) demonstrated a significant reduction in
viral load in treatment-naive patients infected with human
immunodeficiency virus (HIV). The mean reduction in viral load at the
end of the treatment phase ranged from 1.67 log10 copies/m... |
| | | February 02, 2004 | Incyte to Close Palo Alto Facilities, Reduce Workforce by 57 Percent, Focus Resources on Drug Discovery and Development| Company Reports 2003 Results and Provides 2004 Financial Guidance
Conference Call and Webcast Scheduled for Today at 5:30 p.m. ET
Incyte Corporation (Nasdaq:INCY) announced today that it will
close its Palo Alto, California research facilities and headquarters,
effective April 2, 2004, completing its transition to a drug discovery
and development company. As a result, Incyte will reduce its workforce
by 257 employees and expects to eliminate approximately $50 million in
annual ... |
| | | January 30, 2004 | Incyte to Report 2003 Financial Results and Provide 2004 Financial Guidance on February 2nd| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 30, 2004--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
2003 financial results conference call for 5:30 p.m. EST on Monday,
February 2, 2004. The schedule for the press release and conference
call are as follows:
Q4/2003 Press Release: Feb. 2, 2004 at 4:00 p.m. EST
Q4/2003 Conference Call: Feb. 2, 2004 at 5:30 p.m. EST
Domestic Dial In Number: 1-877-692-2592
... |
| | | January 15, 2004 | Incyte and Roche Diagnostics Sign Agreement; Roche Diagnostics will License Incyte's Linear RNA Amplification Technologies for Gene Expression Profiling| PALO ALTO, Calif. & BEVERLY, Mass.----Jan. 15,
2004--Incyte Corporation (NASDAQ:INCY) announced today the signing of
a license agreement with Roche Diagnostics for the use of Incyte's
Eberwine Linear RNA Amplification technology. Roche expects to use the
technology in its development of novel diagnostics that identify gene
expression patterns unique to particular diseases or disease subtypes.
Robust and reliable linear amplification of RNA is a critical
component in the understanding of c... |
| | | December 16, 2003 | Incyte Announces New General Counsel| WILMINGTON, Del.--Dec. 16, 2003--Incyte
Corporation (NASDAQ:INCY) announced today the appointment of Patricia
A. Schreck to the position of executive vice president and general
counsel, reporting to Paul Friedman, M.D., Incyte's chief executive
officer.
Pat joins Incyte from Elan Drug Delivery where she was chief
patent counsel. Pat also served as general counsel for diaDexus LLC, a
joint venture between Incyte and GlaxoSmithKline (GSK) established in
1997 to discover and commercia... |
| | | November 07, 2003 | Company Profile for Incyte Corporation| Nov 07, 2003 -- Incyte is a drug discovery company that is
using its expertise in genomics, medicinal chemistry and molecular,
cellular and in vivo biology to discover and develop novel
therapeutics. The company has three internal drug discovery programs
underway focused primarily on the identification of new small molecule
drugs for cancer and inflammation.
Incyte believes it has the largest compilation of information
regarding full-length human genes and the proteins they encode and... |
| | | November 04, 2003 | Incyte Reports Third Quarter 2003 Financial Results; Expands Pipeline, Advances CCR2 Receptor Antagonist Program| WILMINGTON, Del.--Nov. 4, 2003--Incyte
Corporation (Nasdaq:INCY) today announced financial results for the
quarter ended September 30, 2003, and updated shareholders on recent
corporate accomplishments, including:
the in-licensing of Reverset(TM), a Phase II clinical compound
that is being developed as a treatment for human
immunodeficiency virus (HIV);
the identification of a lead oral CCR2 receptor antagonist
compound which is expected t... |
| | | October 10, 2003 | Incyte to Report Third Quarter 2003 Financial Results on November 4th| WILMINGTON, Del.--Oct. 10, 2003--Incyte
Corporation (Nasdaq:INCY) announced today that it has scheduled its
third quarter 2003 financial results conference call for 4:30 p.m. EST
on Tuesday, November 4, 2003. The schedule for the press release and
conference call are as follows:
Q3/2003 Press Release: 4:00 p.m. EST
Q3/2003 Conference Call: 4:30 p.m. EST
Domestic Dial In Number: 1-877-692-2592
International Dial In Number: 1-973-582-... |
| | | October 10, 2003 | Incyte To Provide Disease-Specific Data Free of Charge| Breast Cancer Awareness Month Coincides with Company's Monthly Offering of Complimentary Disease Profiles
PALO ALTO, Calif. & BEVERLY, Mass--Oct. 10,
2003--Incyte Corporation announced today the addition of the "Disease
Spotlight" to the company's website. Available to the general public,
the Disease Spotlight is a complimentary monthly sampling of Incyte's
Disease View Reports, a component of the company's recently enhanced
information product, the Proteome BioKnowledge Library (BKL). ... |
| | | October 01, 2003 | Incyte Appoints David C. Hastings As Chief Financial Officer| WILMINGTON, Del.--Oct. 1, 2003--Incyte
Corporation (Nasdaq:INCY) announced today the appointment of David C.
Hastings as executive vice president and chief financial officer. Mr.
Hastings has more than 18 years of finance, accounting and operations
experience in the biotechnology industry through prior positions with
ArQule, Inc., Genzyme, Sepracor Inc. and PriceWaterhouseCoopers. Mr.
Hastings will join Incyte on October 14 and report to Paul Friedman,
M.D., Incyte's chief executive offic... |
| | | September 22, 2003 | Incyte To Present At The UBS Global Life Sciences Conference| WILMINGTON, Del., Sep 22, 2003 -- Incyte
Corporation (Nasdaq:INCY) announced today that Paul Friedman, M.D.,
chief executive officer of Incyte, will speak at the UBS Global Life
Sciences Conference in New York at 11:30 a.m. EDT on Wednesday,
September 24, 2003.
A live audio webcast of Dr. Friedman's presentation may be
accessed on Incyte's website at www.incyte.com/webcasts .
About Incyte
Incyte is a drug discovery company that is using its expertise in
genomics, medici... |
| | | September 10, 2003 | Incyte Announces New Senior Management Post| PALO ALTO, Calif. & WILMINGTON, Del.--Sept. 10,
2003--Incyte Corporation (Nasdaq:INCY) announced today the appointment
of John A. Keller, Ph.D., as executive vice president and chief
business officer, a new position reporting to Paul Friedman, M.D.,
Incyte's chief executive officer. Dr. Keller will join Incyte on
September 22, 2003.
Dr. Keller has been with GlaxoSmithKline (GSK) since its formation
in 2001 and with SmithKline Beecham since 1987. In his most recent
position as vice ... |
| | | September 08, 2003 | Incyte and Pharmasset Enter into a Collaborative Licensing Agreement for a Phase II HIV Drug| WILMINGTON, Del. & ATLANTA, Sep 8, 2003 -- Incyte
Corporation (Nasdaq: INCY) and Pharmasset, Ltd. announced today that
they have entered into a collaborative licensing agreement to develop
and commercialize the antiretroviral drug Reverset(TM), also known as
RVT, D-D4FC or DPC-817, which is currently in Phase IIa clinical
development for the treatment of human immunodeficiency virus (HIV)
infections under an approved US FDA Investigational New Drug (IND)
application. Incyte will pay Phar... |
| | | August 28, 2003 | Incyte To Present At The BioCentury NewsMakers Conference| PALO ALTO, Calif. & WILMINGTON, Del.--Aug. 28,
2003--Incyte Corporation (Nasdaq:INCY) announced today that Paul
Friedman, M.D., chief executive officer of Incyte, will speak at the
BioCentury NewsMakers in the Biotech Industry Conference at 9:30 a.m.
ET on Thursday, September 4, 2003.
A webcast of the presentation can be accessed at:
www.incyte.com/webcasts .
About Incyte
Incyte is a drug discovery company that is using its expertise in
genomics, medicinal chemistry a... |
| | | August 26, 2003 | Incyte Appoints Richard Levy, M.D. Senior Vice President, Drug Development| WILMINGTON, Del.--Aug. 26, 2003--Incyte
Corporation (Nasdaq:INCY) announced today that Richard Levy, M.D., has
joined the company as senior vice president, drug development. Dr.
Levy has over 12 years of experience in the pharmaceutical and
biotechnology sectors through his prior positions at Celgene, DuPont
Pharmaceuticals and Novartis.
"Rich has extensive clinical research, regulatory and product
development skills and has worked in multiple therapeutic areas
including HIV, cance... |
| | | August 22, 2003 | Incyte Announces Management Change| WILMINGTON, Del. & PALO ALTO, Calif.--Aug. 22,
2003--Incyte Corporation (Nasdaq:INCY) announced today that Robert
Stein, M.D., Ph.D., has resigned from Incyte to take a senior position
at a leading west coast life science company. Dr. Stein has served as
president and chief scientific officer of Incyte and as a member of
its board of directors since November of 2001.
Paul Friedman M.D., CEO of Incyte stated, "Bob has made meaningful
contributions to Incyte over the past year and a h... |
| | | August 11, 2003 | Incyte Launches Information Product Enhancements for LifeSeq® Foundation and Proteome BioKnowledge® Library|
- Most powerful information products address needs of biotechnology companies -
Palo Alto, CA, and Boston, MA, August 11, 2003 -- Incyte Corporation (Nasdaq: INCY) today announced the release of key enhancements and features to its LifeSeq® Foundation database and software and to its Proteome BioKnowledge® Library. The new LifeSeq installments offer online access to information, new data linkage capabilities, and licensing terms favorable for discovery research. In an effort to furt... |
| | | July 30, 2003 | Incyte Reports Second Quarter 2003 Financial Results; Progress in Drug Discovery, Information Product Development| PALO ALTO, Calif.--July 30, 2003--Incyte
Corporation (Nasdaq:INCY) today announced its second quarter financial
results and reported on the following corporate initiatives:
Identification of novel small molecule CCR2 receptor
antagonists suitable for preclinical development
Consolidation of drug discovery activities in Wilmington,
Delaware
Development of a new biocuration product to consolidate the
company's three leading informat... |
| | | July 21, 2003 | Incyte to Report Second Quarter 2003 Financial Results on July 30th| PALO ALTO, Calif.--July 21, 2003--Incyte
Corporation (Nasdaq:INCY) announced today that it will report second
quarter fiscal year 2003 financial results on Wednesday, July 30,
2003. The schedule for the press release and conference call are as
follows:
Q2/2003 Press Release: 4:00 p.m. Eastern
Q2/2003 Conference Call: 4:30 p.m. Eastern
Domestic Dial In Number: 800-316-4678
International Dial In Number: 706-643-3414
Visit www.incyte.com/we... |
| | | June 24, 2003 | Richard U. De Schutter Elected Chairman of Incyte Corporation Board of Directors| Richard U. De Schutter Elected Chairman of Incyte Corporation Board of Directors
PALO ALTO, Calif.--June 24, 2003--Incyte Corporation (Nasdaq:INCY - News) announced today that Richard U. De Schutter has been elected Chairman of its Board of Directors.
Mr. De Schutter has served on the Incyte Board of Directors since January 2002. From January to October 2001, he was Chairman and Chief Executive Officer of the DuPont Pharmaceuticals Company. Prior to assuming this position, and preced... |
| | | June 02, 2003 | Incyte Presentation At the Needham & Company Second Annual Biotechnology Conference to Be Webcast Live| PALO ALTO, Calif.--June 2, 2003--Incyte Corporation (Nasdaq:INCY - News) Chief Executive Officer Paul A. Friedman, M.D. will speak at the Needham & Company Second Annual Biotechnology Conference in New York, NY on June 5, 2003 at 10:30 a.m.
Interested parties can access a live audio webcast of the presentation and slide materials at http://www.twst.com/econf/mm/needham5/incy.html . A replay of the presentation will be available by the end of the day and will be archived for 30 days.
... |
| | | May 05, 2003 | Incyte Reports First Quarter 2003 Financial Results| Cites Progress in Chemokine Receptor Antagonist Drug Discovery Program
Announces Organizational Change to Strengthen Management of Key
Programs
PALO ALTO, Calif.--May 5, 2003--
Incyte Corporation (Nasdaq:INCY) today reported financial results
for the first quarter ended March 31, 2003.
"First quarter results were in line with our expectations," stated
Paul A. Friedman, M.D., Chief Executive Officer of Incyte.
"Operationally, improvements to the information products have be... |
| | | April 24, 2003 | Incyte Presentation At Deutsche Bank Health Care Conference To Be Webcast Live| PALO ALTO, Calif., Apr 24, 2003 -- Incyte
Corporation (Nasdaq: INCY) Chief Executive Officer Paul A. Friedman,
M.D. will speak to the investment community at the Deutsche Bank
Health Care Conference in Baltimore, Maryland, on May 6, 2003 at 4:00
p.m.
Interested investors can access a live audio webcast of the
presentation and slide materials at
http://www.visualwebcaster.com/event.asp?id=14042 . A replay of the
presentation will be available by the end of the day and will be
arch... |
| | | April 24, 2003 | Incyte Launches New Corporate Web Site| PALO ALTO, Calif., Apr 24, 2003 -- Incyte
Corporation (Nasdaq:INCY) announced today that it has launched a new
corporate Web site, www.incyte.com , to reflect Incyte's broader
mission as a drug discovery company and a leading provider of
discovery research products.
The new site provides current information about Incyte's drug
discovery programs and emerging drug pipeline. It also describes
Incyte's genomic and proteomic information products, LifeSeq(R)
Foundation, ZooSeq(TM), Prot... |
| | | April 21, 2003 | Incyte To Report First Quarter 2003 Financial Results On May 5, 2003| PALO ALTO, Calif.--April 21, 2003--Incyte
Corporation (Nasdaq:INCY) announced today that it will report first
quarter fiscal year 2003 financial results on Monday, May 5, 2003.
The schedule for the press release and conference call are as
follows:
-- Q1/2003 Press Release: 4:00 p.m. Eastern
-- Q1/2003 Conference Call: 4:30 p.m. Eastern
-- Domestic Dial In Number: 877-692-2592
-- International Dial In Number: 973-582-2700
If you ar... |
| | | March 03, 2003 | Incyte To Present At Lehman Brothers Sixth Annual Global Healthcare Conference| PALO ALTO, Calif., Mar 3, 2003 -- Incyte Genomics, Inc.
(Nasdaq: INCY) announced today that the company will present at the Lehman
Brothers Sixth Annual Global Healthcare Conference at 1:30 p.m. (EST) on
Wednesday March 5. Robert Stein, M.D., Ph.D., president and chief scientific
officer of Incyte, will provide an overview of the company and discuss its
outlook for 2003.
The presentation will be webcast live over the internet and can be accessed at:
http://customer.ibeam.com/LEHM002/... |
| | | February 24, 2003 | Incyte to Present at the BIO CEO & Investor Conference| PALO ALTO, Calif., Feb 24, 2003 -- Incyte Genomics, Inc.
(Nasdaq:INCY) today announced that the company will present at the BIO CEO &
Investor Conference at 10:30 a.m. EST on Thursday, February 27th, 2003, in New
York City at the Waldorf Astoria.
Robert Stein, M.D., Ph.D., president and chief scientific officer of Incyte,
will provide an overview of the company and its outlook for 2003.
The presentation will be webcast live over the internet and can be accessed at:
http://www.firs... |
| | | February 19, 2003 | Incyte Reports 2002 Financial Results, Provides Outlook for 2003| PALO ALTO, Calif., Feb 19, 2003 -- Incyte Genomics, Inc.
(Nasdaq:INCY) today announced its financial results for the fourth quarter and
fiscal year ended December 31, 2002.
Paul A. Friedman, M.D., Incyte's chief executive officer, stated, "During 2002,
we took meaningful steps to strengthen our company and accelerate our transition
into drug discovery through the establishment of an experienced and focused drug
discovery group in Delaware, the acquisition of Maxia Pharmaceuticals, the
... |
| | | February 19, 2003 | Incyte Acquires Maxia Pharmaceuticals; Acquisition Expands Drug Discovery & Development Programs| PALO ALTO, Calif., Feb 19, 2003 (BUSINESS WIRE) -- Incyte Genomics, Inc.
(Nasdaq:INCY) today announced that it has completed its acquisition of Maxia
Pharmaceuticals, Inc., a privately-held small molecule drug discovery and
development company located in San Diego, CA.
Maxia will continue to operate in San Diego as a wholly-owned subsidiary of
Incyte.
Under the terms of the acquisition, Maxia will receive up to $28.3 million in
cash and stock and up to $14 million in future clinical... |
| | | February 04, 2003 | Incyte Expands Proteome BioKnowledge Library with Information Linking Human Protein Function to Disease; New Offering Helps Research Scientists Prioritize Drug Targets| PALO ALTO, Calif., Feb 4, 2003 (BUSINESS WIRE) -- Incyte Genomics, Inc.
(Nasdaq:INCY) has enhanced its Proteome BioKnowledge(R) Library with new
information to help research scientists prioritize drug targets by identifying
the connections between proteins and diseases and displaying that information in
a convenient search-and-view format.
This expansion will be helpful in understanding disease mechanisms and potential
uses of proteins in treating diseases.
Incyte's new collection o... |
| | | January 30, 2003 | Incyte Genomics to Report Fourth Quarter 2002 Financial Results on February 19, 2003|
PALO ALTO, Calif.--(BUSINESS WIRE)--Jan. 30, 2003--Incyte
Genomics, Inc. (Nasdaq:INCY), announced today that it will report
fourth quarter fiscal year 2002 financial results on Wednesday,
February 19, 2003. The schedule for the press release and conference
call are as follows:
-- Q4/2002 Press release: 4:00 p.m. ET
-- Q4/2003 Conference Call: 4:30 p.m. ET
-- Domestic Dial In number: 877-692-2592
-- International D... |
| | | January 06, 2003 | Incyte to Webcast Presentation From the 21st Annual JP Morgan H&Q Healthcare Conference|
PALO ALTO, Calif.--(BUSINESS WIRE)--Jan. 6, 2003--Incyte Genomics,
Inc. (Nasdaq:INCY), announced today that its presentation at the
JPMorgan 21st Annual Healthcare Conference will be webcast live by
JPMorgan and can be accessed by registering at:
http://www.mapdigital.com/jpmorgan/healthcare03/directlinks/
go.php?p=incyte_genomics .
Paul A. Friedman, M.D., Incyte's Chief Executive Officer, will
present an overview of the company and its business strategy. The
half-hour p... |
| | | December 16, 2002 | Incyte Genomics to Become Incyte Corporation; Shift from `Genomics' Reflects Drug Discovery Progress and New Information Products|
PALO ALTO, Calif.--Dec. 16, 2002--Incyte
Genomics, Inc. (Nasdaq:INCY) announced today that it will change its
corporate name to Incyte Corporation, reflecting the company's broader
mission as both a drug discovery company and a leading provider of
discovery research products. The name change will take effect in 2003.
"This decision was driven by the desire to unify our genomic and
proteomic information business, intellectual property and rapidly
growing drug discov... |
| | | November 12, 2002 | Incyte Announces $88 Million Expense Reduction, Launch of Its First Drug Discovery Program and Third Quarter 2002 Financial Results|
PALO ALTO, Calif.--Nov. 12, 2002--Incyte
Genomics, Inc. (Nasdaq:INCY) today announced a program to eliminate
$88 million of expenses, the launch of its first fully-staffed drug
discovery program and its third quarter financial results.
Incyte plans to eliminate approximately 37 percent of its
700-person work force immediately and consolidate its Palo
Alto, California office and research facilities.
The company intends to take a one-time charge of up to ... |
| | | November 12, 2002 | Incyte Announces Agreement to Acquire Maxia Pharmaceuticals|
PALO ALTO, Calif. & SAN DIEGO---Nov. 12,
2002--Incyte Genomics, Inc. (Nasdaq:INCY) announced today that it has
agreed to acquire Maxia Pharmaceuticals, Inc., a privately-held small
molecule drug discovery company based in San Diego, California, for up
to $28.3 million in cash and stock and up to $14 million in future
clinical performance milestone payments. Maxia, which currently has 28
employees, is developing compounds to treat chronic and
life-threatening conditions such ... |
| | | October 31, 2002 | Incyte Genomics to Report Third Quarter 2002 Financial Results On November 12| PALO ALTO, Calif., Oct 31, 2002 (BUSINESS WIRE) -- Incyte Genomics, Inc.
(Nasdaq:INCY), announced today that it will report third quarter fiscal year
2002 financial results on Tuesday, November 12, 2002 after the close of the
stock market.
Incyte's senior management will host a conference call on Tuesday, November 12,
2002 at 2:00 p.m. PST to discuss the company's third quarter 2002 financial
results and recent activities. The domestic dial in number for the conference
call will be 800... |
| | | September 04, 2002 | Incyte Genomics Issues Revised Financial Guidance for Fiscal 2002| PALO ALTO, Calif., Sep 4, 2002 -- Incyte Genomics, Inc.
(Nasdaq:INCY) today announced revised revenue and net loss guidance for the
fiscal year ending December 31, 2002. The company estimates that revenue for the
year will be between $100 and $130 million. It had previously issued annual
revenue guidance between $130 and $150 million.
The Company estimates that the net loss for the year will be in the range of $75
to $98 million. Previous net loss guidance for the year was in the range ... |
| | | July 25, 2002 | Incyte Genomics Reports Financial Results for the Second Quarter of Fiscal 2002| PALO ALTO, Calif., Jul 25, 2002 -- Incyte Genomics, Inc., a
leader in genomics-advantaged therapeutic discovery (Nasdaq:INCY), today
reported its consolidated financial results for the second quarter ended June
30, 2002.
The Company reported revenues associated with the information product line
(which includes database subscriptions, partnership programs and licensing
activities) of $27.9 million for the second quarter of 2002 compared to revenues
of $43.2 million for the same period ... |
| | | July 15, 2002 | Incyte Genomics and the University of Cambridge Report New Cause of Severe Insulin Resistance; Findings Have Implications for the Treatment of Type 2 Diabetes|
PALO ALTO, Calif.--July 15, 2002--Incyte
Genomics, Inc. (Nasdaq:INCY), today reported the publication of a
paper on July 15, 2002 in the scientific journal Nature Genetics
titled, "Digenic Inheritance of Severe Insulin Resistance in a Human
Pedigree." The study findings are the result of an ongoing
collaboration between Incyte Genomics and world-renowned researchers
at the University of Cambridge Departments of Clinical Biochemistry,
Medicine, and Public Health, at Addenbrooke's ... |
| | | July 11, 2002 | Incyte Genomics Sets Date for Second Quarter Fiscal 2002 Earnings Announcement| PALO ALTO, Calif., Jul 11, 2002 -- Incyte Genomics, Inc.
(Nasdaq:INCY), announced today its intention to release second quarter fiscal
year 2002 earnings results on Thursday, July 25, 2002 after the close of the
stock market.
Company management will host a conference call on Thursday, July 25, 2002 at
2:00 p.m. PDT to discuss the company's results. The domestic dial in number for
the conference call will be 888/964-4739 and the international dial in number
will be 973/582-2737. A repl... |
| | | May 01, 2002 | Incyte Genomics Reports Financial Results for the First Quarter of Fiscal 2002| PALO ALTO, Calif., May 1, 2002 --
Incyte Genomics,
Inc. (Nasdaq:INCY), today reported its consolidated financial results
for the first quarter ended March 31, 2002.
The Company reported revenues associated with the information
product line (inclusive of database subscriptions, partnership
programs and licensing activities) of $27.0 million for the quarter
ended March 31, 2002 compared to revenues of $37.0 million for the
same period of the previous year. The decrease in these rev... |
| | | April 23, 2002 | GeneFormatics and Incyte Genomics Sign Collaborative Agreement to Annotate Functions of Protein Sequences| SAN DIEGO and PALO ALTO, Calif., Apr 23, 2002 -- GeneFormatics
Inc. and Incyte Genomics Inc. (Nasdaq:INCY) today announced that they have
entered into a collaborative research agreement.
Under the terms of the agreement, GeneFormatics will use its proprietary and
integrated structural proteomics technologies to identify the function and
associated structure of proprietary full-length human protein sequences provided
by Incyte. Information generated may be utilized by Incyte to enable it... |
| | | April 18, 2002 | Incyte Sets Date for First Quarter Fiscal 2002 Earnings Announcement| PALO ALTO, Calif., Apr 18, 2002-- Incyte Genomics, Inc.
(Nasdaq:INCY), the leading genomic information company, announced today the
intention to release its first quarter fiscal year 2002 earnings results on
Wednesday, May 1, 2002 after the close of the stock market.
Company management will host a conference call on Wednesday, May 1, 2002 at 2:00
p.m. PDT to discuss the company's results. The domestic dial in number for the
conference call will be 800-231-5571 and the international dial... |
| | | April 02, 2002 | Incyte Genomics and LION bioscience Collaborate to Provide Broader Access to Drug Target Information|
PALO ALTO, Calif.----April 1, 2002--
Strategic Collaboration To Make Industry-Leading
LifeSeq(R) Database Available To Scientists Through
Web-Based Integration Platform
Incyte Genomics, Inc. (Nasdaq:INCY), the leading genomics
information company, and LION bioscience, (Nasdaq:LEON) (Neuer
Markt:LIO, WKN 504 350), the leading provider of integrated
information technology services for the life sciences, today announc... |
| | | March 04, 2002 | Leading Genomic Research Firm Chooses Delaware As Location For New East Coast Facility|
NEWARK, Del. & PALO ALTO, Calif.----March 4, 2002--
Delaware state officials announced today that Incyte Genomics, Inc.
(Nasdaq:INCY), headquartered in Palo Alto, California, has signed a
lease agreement with DuPont to locate its first East Coast
biotechnology research operation in the Stine-Haskell Research Center
in Newark, Delaware. Incyte plans to occupy the space in March 2002.
The opening of the new operation is expected to create over 80
jobs this year, the majority... |
| | | February 25, 2002 | First Comprehensive Chemogenomics System for Drug Discovery and Optimization Launched; DrugMatrix Introduced by Incyte Genomics and Iconix Pharmaceuticals| PALO ALTO, Calif., and MOUNTAIN VIEW, Calif., Feb 25, 2002 --
Incyte Genomics, Inc. (Nasdaq:INCY), the leading genomics information company,
and Iconix Pharmaceuticals, Inc., an industry pioneer in chemogenomics, today
announced the commercial release of DrugMatrix(TM). DrugMatrix is the first
comprehensive research tool in the emerging field of chemogenomics that enables
researchers to select the highest quality leads and drug candidates at the
earliest, most cost-effective stages of dru... |
| | | February 14, 2002 | Ambion Licenses RNA Amplification Patents from Incyte Genomics| AUSTIN, Texas and PALO ALTO, Calif., Feb 14, 2002 -- Ambion,
Inc. announced it obtained a non-exclusive license from Incyte Genomics (Nasdaq:
INCY) to manufacture and sell amplification kits for research use under patents
directed to the RNA amplification procedure developed by Van Gelder, Eberwine
and colleagues. Linear RNA amplification technology is used to increase the
levels of RNA expressed in cells to quantities that can be used for obtaining
gene expression patterns on DNA microar... |
| | | February 13, 2002 | Incyte Reports 2001 Fourth Quarter and Year End Financial Results| PALO ALTO, Calif., Feb 13, 2002 -- Incyte Genomics, Inc.
(Nasdaq:INCY), the leading genomic information company, today reported its
consolidated financial results for the fourth quarter and fiscal year ended
December 31, 2001.
"Fiscal 2001 concluded for Incyte on a high note," said Paul A. Friedman, M.D.,
Chief Executive Officer for Incyte. "My appointment and Bob Stein's appointment
as President and Chief Scientific Officer in November were quickly followed by
the recruitment of a nu... |
| | | February 07, 2002 | Brian Metcalf, Ph.D., Appointed Executive Vice President and Chief Drug Discovery Scientist for Incyte Genomics; Dr. Metcalf Also Named Site Head for Incyte's New East Coast Operations| PALO ALTO, Calif., Feb 7, 2002 -- Incyte Genomics, Inc.
(Nasdaq:INCY), the leading genomic information company, announced today that
Brian Metcalf, Ph.D., has been appointed Executive Vice President and Chief Drug
Discovery Scientist for Incyte Genomics. Dr. Metcalf will join Incyte on
February 7, 2002, reporting to Robert Stein, M.D, Ph.D., Incyte's President and
Chief Scientific Officer.
Brian Metcalf, Ph.D., was most recently Vice President and Chief Scientific
Officer with Kosan B... |
| | | February 04, 2002 | Incyte Sets Announcement Date for Fourth Quarter Fiscal 2001 Earnings Release| PALO ALTO, CA, February 4, 2002 – Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, announced today its intention to release fourth quarter fiscal year 2001 earnings results on Wednesday, February 13, 2002 after the close of the stock market.
Company management will host a conference call on Wednesday, February 13, 2002 at 2:00 p.m. PST to discuss the company's results. The domestic dial in number for the conference call will be (877) 692-2588 and the internatio... |
| | | January 14, 2002 | Incyte Genomics Appoints Richard U. De Schutter and Paul A. Brooke to its Board of Directors| PALO ALTO, CA, January 14, 2002 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company announced today the appointment of Richard U. De Schutter and Paul A. Brooke to its Board of Directors.
Richard De Schutter was previously the Chairman and Chief Executive Officer of the DuPont Pharmaceuticals Company. Before assuming this position in 2000, he had been the Vice-Chairman, Chief Administration Officer, and a Director of the Monsanto Company, a leading life sciences... |
| | | January 04, 2002 | Incyte Genomics Presentation to be Webcast by JP Morgan H&Q from its 20th Annual Healthcare Conference| PALO ALTO, CA, January 4, 2002—Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company announced today that its presentation at the JP Morgan H&Q Healthcare Conference will be webcast live by JP Morgan and can be accessed by registering at http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html .
Paul A. Friedman, M.D., Chief Executive Officer and Robert Stein, M.D., Ph.D., President and Chief Scientific Officer will present an overview of the company and... |
| | | December 21, 2001 | Affymetrix and Incyte Genomics Settle All Patent Infringement Litigation| Palo Alto, CA, and Santa Clara, CA, December 21, 2001—Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company, and Affymetrix, Inc., the leader in creating breakthrough tools for the genomic revolution (Nasdaq: AFFX), today announced a comprehensive settlement of all existing infringement litigation between the two companies. The first lawsuit involved several of Affymetrix microarray-related patents (U.S. Patent Nos. 5,445,934, 5,744305, 5,800,992, 5,871,928, 6,040,193). ... |
| | | December 19, 2001 | Cambridge Antibody Technology Gains Access To Incyte LifeSeq® Gold Database And Options To Develop And Commercialize Human Therapeutic Antibody Products| Palo Alto, CA, and Melbourn, England, December 19, 2001—Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company, and Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT), today announce an agreement which gives CAT access to the Incyte LifeSeq ® Gold database and options for product development rights.
Under the terms of the agreement, CAT will receive access to Incyte's LifeSeq ® Gold database and to high quality, sequence verified human cDNA clones and rig... |
| | | November 26, 2001 | Incyte Genomics Names Paul A. Friedman, M.D., Chief Executive Officer and Robert Stein, M.D., Ph.D., President and Chief Scientific Officer| Roy Whitfield Elected Chairman of the Board
Palo Alto, CA, November 26, 2001—Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company,
today named Paul A. Friedman, M.D.—formerly President of DuPont Pharmaceuticals Research Laboratories—to be Incyte's
Chief Executive Officer. In addition, Incyte named Robert Stein, M.D., Ph.D.—formerly DuPont Pharmaceuticals Executive
Vice President of Research and Preclinical Development—as President and Chief Scientifi... |
| | | November 20, 2001 | Dr. Reddy's Laboratories Limited Announce Agreement for Utilizing Incyte LifeSeq® Gold Online| LifeSeq ® Gold to Further Advance Dr. Reddy's Research and Development Programs in Cancer, Diabetes, Infectious Diseases and Pain Therapeutic Development Through Genomics
Palo Alto, CA, Hyderabad, India and Atlanta, Georgia, November 20, 2001 - Dr. Reddy's Laboratories Limited (NYSE: RDY), an emerging global pharmaceutical company, and Reddy US Therapeutics, Inc. ("Reddy US"), a wholly-owned subsidiary of Dr. Reddy's, and Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic inf... |
| | | October 25, 2001 | Incyte Genomics Reports Record Revenues for Third Quarter 2001| Announces Restructuring to Focus on Its Core Information Business and Leverage Its Industry-Leading Intellectual Property Portfolio in Licensing and Therapeutic Discovery While Improving Overall Operating Performance
Palo Alto, CA October 25, 2001 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, today reported consolidated financial results for the three and nine months ended September 30, 2001. Incyte also announced a restructuring that includes plans... |
| | | October 23, 2001 | Incyte Genomics Reschedules Third Quarter Fiscal 2001 Results Release and Conference Call| Palo Alto, CA, October 23, 2001 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, announced today it is rescheduling its third-quarter fiscal year 2001 release of results and management conference call for Thursday, October 25, 2001 at 9:30AM PDT.
The release had been scheduled for October 24. The date was changed to avoid scheduling conflicts.
Company management will host a conference call on Thursday, October 25, 2001 at 9:30 a.m. PDT t... |
| | | October 23, 2001 | Incyte Genomics Signs Exclusive Patent Agreement with Genentech to Enable Commercialization of Therapeutic Antibodies to Four Proteins| First Antibody Outlicensing Agreement for Incyte Genomics, the Holder of the Industry's Largest Commercial Portfolio of Patented Full-Length Genes, Antibodies and Proteins
Palo Alto, CA October 23, 2001 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, today announced the exclusive licensing by Genentech, Inc. (NYSE: DNA) of Incyte patent rights covering therapeutic antibodies to four proteins discovered by Incyte. Incyte is entitled to receive clinical de... |
| | | October 18, 2001 | Medarex and Incyte Genomics Announce Partnership to Develop and Commercialize Fully Human Antibody Therapeutics| Partnership Will Leverage Incyte's Industry Leading Commercial Portfolio of Patented
Full-Length Genes, Proteins and Antibodies with Medarex's Human Antibody Technology
Princeton, NJ and Palo Alto, CA; October 18, 2001 - Medarex, Inc. (Nasdaq: MEDX) and Incyte Genomics, Inc. (Nasdaq: INCY),
the leading genomics information company, today announced a collaboration for the development of fully human antibody therapeutics.
Under the terms of the agreement, Medarex a... |
| | | October 15, 2001 | Incyte Genomics Receives Favorable Court Ruling Invalidating Affymetrix Patent| Further Court Summary Judgement Decisions Hold Other Affymetrix Patent Claims Not Infringed by Incyte
Palo Alto, CA, October 15, 2001 - Incyte Genomics, Inc. (Nasdaq:INCY), the leading genomics information company,
announced today that the U.S. District Court for the Northern District of California has granted a victory to
Incyte by issuing a summary judgement ruling on October 3, 2001 in favor of Incyte for the remaining two
disputed claims of the "two-color" patent present... |
| | | October 10, 2001 | Incyte Genomics and Epoch Biosciences Enter into License, Development and Supply Alliance| PALO ALTO, CA, and BOTHELL, WA, October 10, 2001 - Incyte Genomics, Inc (Nasdaq: INCY), the leading genomics
information company, and Epoch Biosciences, Inc. (Nasdaq: EBIO), a leading provider of proprietary chemistries
and reagents that enable genomic research, announced today an alliance designed to leverage the intellectual
property assets of both companies. The alliance consists of three elements: Incyte's license to Epoch for access
to LifeSeq® Gold and ZooSeq™ to allow dev... |
| |
|
| 
|
